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1.1 SOLUBLE ANALOGUES OF PYRROLO- AND PYRAZOLO-
[g]QUINAZOLINES AS EGFr INHIBITORS: SYNTHESIS,
BIOLOGICAL EVALUATION AND MODELLING OF THE MODE OF BINDING, Brian
D. Palmer#*, Susanne Trumpp-KalImeyer+, David W. Fry+, James M. Nelson+, H. D.
Hollis Showalter' and William A. Denny#, 'Cancer Society Research Laboratory,
Faculty of Medicine and Health Science, The University of Auckland School of
Medicine, Private Bag 92019, Auckland, New Zealand, and +Parke-Davis
Pharmaceutical Research, Division of Wamer Lambert Company, 2800 Plymouth
Rd., Ann Arbor, Ml 48106-1047, USA.
Anilinoquinazolines containing pyrrolo- and pyrazolo-fused rings have recently been
identified by us as potent and selective inhibitors of the tyrosine kinase activity of the
epidermal growth factor receptor (EGFr), binding competitively at the ATP site. Thus
the pyrroloquinazoline (1) and the pyrazoloquinazoline (2) both display IC50 values of
0.44 nM for inhibition of the isolated enzyme.
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Such compounds are of interest as anticancer drugs, since EGFr is overexpressed in
many cancers and is associated with poor prognosis. Because the parent tricyclic
ring systems have poor solubility, a series of analogues of (1) and (2) bearing
solubilising sidechains in the 5-membered ring has been prepared and evaluated for
inhibition of the tyrosine kinase activity of isolated EGFr, and for inhibition of its
autophosphorylation in EGF stimulated A431 cells. Several analogues, particularly
C-3 substituted pyrroloquinazolines, retained high potency in both assays, making
them of particular interest for further evaluation.
A model for the binding of the general class of anilinoquinazolines to the EGFr was
constructed from structural information (particulardy for the catalytic subunit of the
cAMP-dependent protein kinase) and from the structure-activity relationships
observed in this series. In this model, the 5-membered pyrrolo- and pyrazolo- rings
occupy the entrance of the ATP binding pocket of the enzyme, with N-1 located at
the bottom of the cleft and the C-3 position pointing towards a pocket corresponding
to the ribose binding site of ATP. This allows considerable bulk tolerance for C-3
substituents, and lesser bulk tolerance for N-1 substituents. The two nitrogen atoms
of the quinazoline ring lie deep in the cleft, occupying similar positions to nitrogen
atoms 1 and 3 of ATP itself. The observed high selectivity of these compounds for
binding to EGFr over other similar tyrosine kinases is attributed to the 4-anilino ring
binding in an adjacent hydrophobic pocket which has an amino acid composition
unique to EGFr.
EXAMINATION OF ANTITUMOUR ACTIVITY OF 2-(4-
1 2 AMINOPHENYL)BENZOTHIAZOLES.
M-S Chual, T.D. Bradshaw", N. Jones2 and M.F.G. Stevensl.1CRC Experimental Cancer
Chemotherapy Research Group, Cancer Research Laboratories, University of Nottinghamn, NG7 2RD,
2CRC Molecular and Cellular Pharmacology Group, School of Biological Sciences, University of
Manchester, M13 9PT.
Analogues of 2-(4-aminophenyl)benzothiazole (CJM 126) substituted with an iodine atom
(DF 129) or methyl group (DF 203) adjacent to the amino group elicit potent growth
inhibitory effects against certain breast, ovarian, lung, renal and colon human-derived
carcinoma cell lines in vitro. DF 203 is also active in vivo against a panel of ER+ and ER-
breast xenografts transplanted in nude mice (Shi etal, J. Med. Chem, 1996, 39, 3375-3384).
Unusual biphasic dose response curves were obtained during the first 72h DF 129 and 96h
DF 203 treatments. IC50 values of 0.78nM and 0.03nM were seen in MCF-7 (ER+) and
MDA 468 (ER-) cell lines respectively following initial seeding at5 x 103 and 72h exposure
DF 129. Additionally, an LC5O value of7.2nM was obtained in MDA 468 cells. However,
in populations exposed to I0)±M or 30tM DF 129 or DF 203, proliferating colonies were
observed: MDA 468 cells revealed a second LC5O value > 30lM. In contrast, following
exposure periods > 72h (DF 129) or > 96h (DF 203) a more conventional dose response is
obtained. Morphological features characteristic of apoptosis were observed as cells, exposed
to 10loM and 30OM drug, die.
Examination ofproteins involved in cellular regulation reveal: decreased p53 expression in
MDA 468 cells following 72h treatment with 300nM and 301kM DF 129 as well as reduced
expression after exposure to 30jM CJM 126; modulation of bcl-2 expression by
benzothiazoles in MCF-7 cell populations. Bcl-2 expression was markedly reduced in cells
following 24h treatment with CJM 126, DF 129 and DF 203 (30RsM). Expression of bcl-2
appeared unchanged after 72h 3OnM DF 203 exposure but a significant decrease in
expression was observed in samples treated with 300nM, 3gM and 30OM DF 203. In
contrast, enhanced expression of bcl-2 was encountered in LT-lOnM and LT-lO1kM, two
MCF-7 variant cell lines exhibiting acquired resistance to CJM 126 (IC50 > 50gM) and
cross resistance to DF 129 and DF 203 (IC50> 30MM).
INVESTIGATIONS INTO THE MECHANISM OF ACTION
1.3 OF CB30865; A LIPOPHILIC QUINAZOLINE ANALOGUE
OF THE ANTIFOLATE ICI 198583. L.A. Skelton*, M.G.
Ormerod, F.D. Mitchell, J. Titley, L. Brunton and A.L. Jackman. CRC Centre
for Cancer Therapeutics at The Inst. of Cancer Res., Sutton, Surrey, UK.
CB30865 is a lipophilic analogue of the antifolate ICI 198583 (2-desamino-2-
methyl-N'°-propargyl-5,8-dideazafolic acid) where the glutamate residue of the
latter is replaced with an aminomethyl 3-pyridine moiety. It is a potent inhibitor
of cell growth in vitro (e.g. WI L2 human lymphoblastoid 72 hour IC50=3nM).
Despite its folate-based structure, CB30865 does not act via inhibition of
known pathways of folate metabolism. It is active in the presence of thymidine
and other end products of folate metabolism, as well as in TS overproducing
cell lines. The biochemical characteristics of CB30865 set it apart from other
antitumour agents. For example, a cell line with acquired resistance to
CB30865 (WlL2:R865; -300 fold) was sensitive to all agents tested including
antimetabolites, DNA interactive agents, spindle poisons, protein
kinase/phosphatase inhibitors, metabolic poisons and various experimental
agents. In addition, CB30865 (3OnM) induces a gross cell cycle effect in that
WlL2 cells arrest simultaneously in all phases of the cell cycle after 20-24
hours exposure. Furthermore, in the NCI in vitro screen, CB30865
demonstrated particularly good activity against colon carcinoma and
leukaemia cell line panels and was COMPARE negative. In the EORTC in
vitro screen, CB30865 was found to be inactive against cdc2 kinase and cdc25
phosphatase. Trypan blue exclusion studies revealed that WlL2 cell
populations exposed to 3OnM CB30865 maintained viability at -60% after 54
hours but were only 12% viable after 72 hours. The same concentration of
CB30865 induced 95% inhibition of colony formation suggesting that those
cells viable after 54 hours are in fact destined to die. Intracellular AMP, ADP
and ATP levels in WlL2 and WlL2:R865 cells in the presence of CB30865
(3OnM) were investigated using HPLC. After 24 hours, the adenylate energy
charge (AEC={[ADPJ/2 + [ATP]}/[AMPJ + [ADP] + [ATP]; an important
measure of cellular energy status) was reduced from 0.96 to 0.86 in WlL2
cells (p<0.05) but was unchanged in WIL2:R865 cells. A combination of 2mM
KCN/6mM deoxyglucose (DG) reduced the AEC of both WlL2 and
WIL2:R865 cells after 24 hours (to 0.87 and 0.93 respectively). However,
viability was reduced to a greater extent in W1L2:R865 populations (10 v. 31%
control, p<0.05). The relevance of these findings to the mechanism of action
of CB30865 is to be evaluated.
1.4 THEIN VITRO BIOLOGICAL ACTIVITIES OF SYNTHETIC
18-0-METHYL MYCALAMDE B,0O-epi-18-0-METHYL
MYCALAMIDE B AND PEDERIN, A.Richter", P.Kocienski2, P.Raubo' and D.E.
Davies'. 'CRC Medical OncologyUnit, Southampton General Hospital, Tremona Road,
Southampton S016 6YD. 2Dept. ofChemistry, University ofSouthampton, S017 1BJ,
Mycalamides A and B, which were originally isolated from a marine
sponge, show close structural similarity to the insect toxin, pederin and
exhibit potent cytotoxicity and antitumour activity. Detailed
investigation of the clinical potential of these compounds has been
hampered because they are available in only minute quantities from
natural sources. We now describe the biological activities of 18-0-
methyl mycalamide B, 1O-epi-18-O-methyl mycalamide and pederin, all
prepared bytotal synthesis. The activities of18-0-methyl mycalamide
B and pederinwerevirtually indistinguishable when evaluated in DNA
or protein synthesis assays, and in cytotoxicity assays using human
carcinoma cell lines (IC50's 0.2-0.6 nM). In all assays,
10-epi-18-O-methyl mycalamide B was 103 times less toxic than its
diastereoisomer demonstrating that the cytotoxicity of 18-0-methyl
mycalamide B isinseparable fromits ability to inhibit protein synthesis.
Short term exposure of squamous carcinoma cells to 18-0-methyl
mycalamide B or pederin caused an irreversible inhibition ofcellular
proliferation and induced cellular necrosis. In contrast, the
antiproliferative effects ofthe compounds on human fibroblasts were
reversible and there was no evidence ofnecrosis. Demonstration that
18-0-methyl mycalamide B and the synthetically less complex
molecule, pederin, show some tumour cell toxicity indicates that this
novel class ofcompounds should, with appropriate modification, be
subjected to preclinical evaluation.
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NU1025, A POTENT POLY(ADP-RIBOSE) POLYMERASE
1.5 INHIBITOR, INIQUCES APOPTOSIS IN A CELL LINE
DEPENDENT MANNER, M.J.Roberts ', N.J.Curtin', B.W.Durkacz', B.T.Golding2, 2 I2 'Cne1 eeac nt R.J.Griffin , A.G.Hall, D.R.Newell', S.Srinivasan. Cancer Research Unit,
2Department ofChemistry, University ofNewcastle-upon-Tyne, UK. NE2 4HH
Poly(ADP)ribose polymerase (PARP), is proteolytically cleaved into
two fragments of85kD and 25kD by specific ICE-like proteases during
apoptosis. Inhibition of the appropriate ICE-like protease prevents
PARP cleavage and also apoptosis, suggesting that PARP cleavage is
necessary for apoptosis to occur. The direct cellular effects of a potent
and specific PARP inhibitor have been studied. NU1025 inhibits
PARP activity with an IC50 of 0.41.M in permeabilised L1210 cells.
NU1025 was growth inhibitory and cytotoxic against A549 cells
(human NSLC), IC50 0.53mM and LD50 0.71mM, respectively. After
exposure to 1mM NU1025 for 24hrs, 38 ± 5% of the cells showed
morphological characteristics ofapoptosis. This level did not increase
over time, and at 96hrs 25 ± 6% of cells were apoptotic. Western
blotting of A549 cells treated with 1mM NU1025 for 24hrs revealed
PARP cleavage. The growth inhibitory IC50 values for HT-29 (colon),
CCRF-CEM (leukaemia) and MCF-7 (breast) cells were in the range
0.34 - 0.62mM, i.e. similar to A549 cells. However, the degree of
apoptosis measured in each cell line following exposure to 1mM
NU1025 was markedly different. A549 cells have a relatively high
level ofapoptosis after 24hrs, while the other cell lines have low levels
at early time points which progressively increase. The apoptotic
fraction forHT-29, CCRF-CEM and MCF-7 cells at 24hrs was 4+ 1%,
3 ± 2% and 3 ± 1%, increasing to 17 ± 5%, 36 + 7% and 12 ± 4% at
96hrs, respectively. FACS analysis of propidium iodide (PI) stained
cells revealed no marked phase specific cell cycle arrest induced by
1mM NU1025 in any ofthe cell lines, although PIbinding appeared to
increase. In summary, these studies indicate that NU1025 can produce
apoptosis in a cell linedependent manner.
1.7 BIOCHEMISTRY OF POTENT CYTOCHROME P45017,,
INHIBITORS. S.Elaine.Barrie', G.A.Potter2, F.C.Chan',
MWarman'. 'CRC Centre for Cancer Therapeutics, Institute ofCancerResearch,
Sutton, Surrey, SM2 5NG. 2Chiroscience Ltd, Cambridge Science Park, Milton Rd,
Cambridge CB4 4WE.
Most cancer ofthe prostate isinitially androgen dependent. Standard
treatments, medical or surgical castration, are effectiveby reducing the
level ofcirculating androgens by ablating the testicular production, but
they do not affect the adrenal production ofandrogens. We have been
developing inhibitors ofthe key enzyme in the androgenicbiosynthetic
pathway, cytochromeP450175.(17a-hydroxylase/C17,20 lyase) as a means
ofablating both testicular and adrenal androgen production. Lead
compounds of two series were selected foractivity against the enzyme
from human testes. When tested in vivo in mice, abiraterone acetate (17-
(3-pyridyl)androsta-5,16-dien-313-O-acetate), but not CB7645 (2-(4-
pyridyl)propan-2-yl 1-adamantanecarboxylate), produced a reduction in
circulating androgens and regression ofandrogen dependent organs.
Studies with the murine testicular enzyme showed that CB7645 was a
reversible competitive inhibitor with aKi lOnM. However theK. for the
substrate progesterone was lower at 4.3nM. Abiraterone (17-(3-
pyridyl)androsta-5,16-dien-33-ol), on the other hand, was found to be an
"irreversible" inhibitor. The inhibition was slow to occur, and was
unaffected by the substrate concentration or by dialysis for 24hr. These
studies have been extended to the human enzyme. CB7645 is a reversible
competitive inhibitor with a Ki < 1 nM compared with aKm of 15nM for
the substrate pregnenolone. Thus CB7645 is a much more potent
inhibitoi ofthe human enzyme than ofthe murine one. Abiraterone was
found to be an "irreversible" inhibitor in vitro, its effect being unaffected
by 24hrdialysis. Abiraterone and CB7645 are both potent inhibitors of
cytochromeP450175 but with different modes ofinhibition which may be
relevant to their potential clinical use.
1 .6 AMD473, A NOVEL PLATINUM ANALOGUE,BIPHASICALILY INDUCES
P53 AND RESULTS IN INCREASED G2 DELAY AND DFIAYED CELI.
DEATH WHEN COMPARED TO CISPLATIN, J. Holford*', B. Murrer2, L. Kelland', 'CRC Centre for
Cancer Therapeutics, Institute ofCancer Research, Sutton, Suffey, 2Johnson Matthey Technology Centre.
Reading.
Our knowledge of the cellular and molecular mechanisms of acquired
cisplatin resistance has enabled the identification of the novel platinum-based
complex cis-amminedichloro(2-methylpyridine) platinum II (AMD473). This
sterically hindered complex displays the ability to circumvent acquired cisplatin
resistance in well characterised human ovarian carcinoma (HOC) cell line models.
(mean resistance factor = 2 +/-0.4 for JM473 compared to 9.1 +/-3.6 for cisplatin
and 7.2 +/-3.6 for carboplatin), where resistance mechanisms are known to include
reduced platinum accumulation, elevated glutathione and metallothionein levels,
and enhanced DNA repair/tolerance. Also, in our panel of intrinsically resistant
HOC cell lines, AMD473 showed only a 30.6 fold increase in IC5C value from the
inost sensitive cell line to the most resistant where with cisplatin it was 117.9 fold.
Alkaline elution studies using HOC cell lines have shown markedly
different rates offormation ofinterstrand DNA cross-links (ISC). With continuous
drug exposure, (200±tM) ISC formation with CDDP was maximal at 4 hours.
where with AMD473, no ISCs could be detected at this time. ISC formation by
AMD473 was detectable from 12 hours and was still increasing at 24 hours. In
wild type p53 HOC cell lines, the delayed formation of ISCs with AMD473 was
accompanied by a biphasic and delayed induction of p53 after treatment with
equitoxic concentrations of CDDP and AMD473. AMD473 also exhibited an
enhanced G2 cell cycle block which coincided with delayed cell detachment when
compared to cells treated with equitoxic concentrations ofCDDP.
In conclusion, our in vitro data show that AMD473, as well as being able
to circumvent many ofthe cellular resistance mechanisms to platinum agents such
as reduced accumulation, glutathione and DNA adduct tolerance/repair, may also
be more effective than cisplatin at producing a G2 cell cycle block possibly via
altered p53 induction kinetics. This may also explain why AMD473 is less
affected by intrinsic resistance mechanisms than cisplatin. Clinical studies of
AMD473 are expected to begin in 1997.
This study was funded by the Cancer Research Campaign, U.K.
1.8 XR9051, A POTENT P-GLYCOPROTEIN INHIBITOR,
REVERSES MULTIDRUG RESISTANCE IN VIVO. *Mistry, P.
Ryder, H. Dale, I. 'Eccles, S. 2Plumb, J. 3Watson, S. Johnson, R. Flatman, K and Bevan, P. Xenova Ltd,
Slough, SLI 4EF; 'ICR, Sutton, SM2 SNG; 2CRC Dept ofOncology, Glasgow, G61 IBD, 3Cancer
Studies Unit, University ofNottingham, NG7 2UH, UK
Expression ofP-glycoprotein (P-gp) is a potential cause ofclinical resistance to
treatment with many anticancer drugs. XR9051 is a potent and specific
inhibitor ofP-gp, which reverses drug resistance in several murine and human
multidrug resistant (MDR) cell lines. Complete reversal ofresistance to a
variety ofcytotoxic drugs, including vincristine (Vcr), doxorubicin (Dox), and
taxol, was observed following 4-6 days coexposure to 0.1-0.5 iM XR9051. In
the current study the in vivo efficacy ofXR9051 was evaluated in murine and
human tumour models. The MC26 murine colon carcinoma cell line exhibits
intrinsic MDR, which is at least in pars, mediated by P-gp. Studies in mice
bearing the MC26 tumours demonstrated that coadministration ofXR9051,
either intraperitoneally or orally (40 mg/kg) significantly (p <0.001) enhanced
the antitumour activity ofDox (5 mg/kg, i.v.). XR9051 also significantly
potentiated the antitumour activity ofDox in an acquired resistant P388/DXJ
murine leukaemia model. Treatment ofP388/DXJ tumourbearing mice was
performed on days 1, 4 and 7 and the results showed that a significant
(p<0.005) increase in median survival time was achieved by Dox (2 mg/kg, i.p.)
in conjunction with XR9051 (40 and 60 mg/kg, i.v. and 60 and 80 mg/kg, p.o.)
compared to Dox alone. In addition, studies in athymic mice bearing human
ovarian (2780AD and CHI/Dox) and small cell lung (H69/LX4) carcinoma
xenografts showed that coadministration ofXR9051 (i.v. or p.o.) could
significantly potentiate the antitumour activity ofVcr, Dox, taxol, epirubicin
and etoposide in a dose dependent manner. Moreover, comparison ofbody
weights ofanimals indicated that the combination schedules ofXR905 I plus
cytotoxic drug used in these studies were well tolerated. These results
demonstrate that XR9051 is a very effective modulator ofP-gp mediated MDR
and could be beneficial in the treatment ofMDR cancers. Phase I clinical
studies in healthy volunteers are currently in progress.Oral Presentations 7
2 i PRODUCTION OF MATRIX METALLOPROTEINASE I
(MMP1) BY BLADDER TUMOUR CELLS FOLLOWING
EGF STIMULATION J.E.Nutt* andJ.Lunec, Cancer Research Unit, Medical School,
University ofNewcastle, Newcastle upon Tyne, NE2 4HH.
The matrix metalloproteinases are a family of enzymes which degrade
the extracellular matrix and are considered to be important in tumour
invasion and metastasis. Levels in bladder cancer have been correlated
with tumour grade and invasion and urinary levels ofMMP2 have been
shown to be elevated in patients with bladder transitional cell
carcinoma2. Epidermal growth factor (EGF) is found in high
concentration in urine and it has been shown that the presence of EGF-
receptor (EGF-R) in bladder cancer is a strong independent predictor of
tumour stage,progression and poorprognosis3. The aim ofthis work is to
study the effect ofEGF onMMP1 expression andproduction in an EGF-
R positive human bladder tumour cell line. RT112 cells were grown in
serum free medium and treated with EGF (10 or 50ng/ml) for 24 or 48
hours. Following treatment, the conditioned medium was collected and
the total MMPI levels were measured using the Biotrak ELISA assay.
MMP1 levels in cell extracts were also measured. Total RNA was
extracted from the cells and used for Northern analysis. On Northern
analysis MMP2 mRNA remained constant whereas levels of MMP1
mRNA were only detectable in EGF treated samples. Extracellular levels
of MMP1 protein in the medium were undetectable in control samples
but were increased from 8ng/ml at 24 hours to 24ng/ml at 48 hours of
EGF treatment. Levels ofMMP1 in all cell extracts remained constant at
the lower level of detection (approx. 4ng/ml). These results demonstrate
that MMP1 production and extracellular secretion is stimulated by EGF
in a bladder tumour cell line. Initial studies have also shown that MMP1
is detectable in urine of patients with bladder tumours and may be
important in theprogression of EGF-receptorpositive tumours and their
prognosis. 1 Davies, B. etal 1993, Cancer Research53, 5365
2Marguilies, I.M. etal1992, CancerEpidemiology 1, 467
3 Mellon, K. etal1995, J. Urol. 153, 919
2.3 REGULATION OF ENDOTHELIAL CD44 EXPRESSION
AND TUMOUR CELL-ENDOTHELIUM ADHESION BY
HEPATOCYTE GROWTH FACTOR/SCAlTER FACTOR, S. Hiscox and W.G.
Jianff.Dartment ofSurgery, University ofWales College ofMedicine, Heath Park,
Hepatocyte growth factor/scatter factor (HGF/SF) has been implicated in the process
of metastasis by its ability to stimulate tumour cell functions such as motility and
invasion that are central to the metastatic cascade.
In order formetastasising tumour cells to establish secondary tumours at distantsites,
they must enter the circulatory system and thus interact with the endothelial cells
lining the circulatory vessels.
CD44 is a cell surface adhesion receptor involved in cell-cell and cell-matrix
interactions and has been implicated in a number of biological process including
lymphocytehoming and tumourprogression.
The aim of this study was to examine the effect of HGF/SF on endothelial CD44
expression and whether this affected tumourcell-endothelium adherence.
Expression of endothelial CD44 following HGF/SF stimulation (40 ng/ml) was
assayedusing an OPD-based ELISA methodtogether with Westernblotting. Tumour
cell adherence to HGF/SF-activated endothelial cell monolayers was assessed by co-
culturing fluorescently-labelled human colon cancer (HTI15) and breast cancer
(MCF7) cells with HGF/SF-activated endothelial cellmonolayers. Endothelial-bound
tumour cells were detectedby a fluorescenceplate reader.
Following stimulation by HGF/SF, expression of CD44 on endothelial cells was
observed to increase in a time dependant manner, with a maximum level response
observed following 60 minutes HGF/SF incubation. These results were confirmed by
Western blotting studies which revealed up-regulation of a 85-90 kDa protein
corresponding to CD44 in response to HGF/SF. The attachment of human colon
cancer and breast cancer cells to endothelial monolayers was seen to increase
following activation ofthe endothelial cells by HGF/SF; the increase in endothelial-
bound tumour cells observed here could be attributed to the CD44 receptor as
inclusion ofanti-CD44 antibodies resulted in a reversal ofthis effect.
We conclude that HGF/SF induces the expression ofthe cell-cell adhesion molecule,
CD44, on the surface of endothelial cells thus facilitating the attachment of tumour
cells to the endothelium. These observations may further implicate HGF/SF in the
process ofmetastasis.
2.2 THE ROLE OF DESMOGLEIN 2 IN INVASION AND METASTASIS OF BREAST CANCER CELLS.
*E.L.Davies,W.G.Jiang,R.Cochrane,R.E.Mansel. Department ofSurgery,
Academic Unit,University Hospital ofWales, Heath Park, Cardiff.
Invasion and distant metastasis ofhuman breast cancer cells is a multistep process
and ofprime importance to the patient. A fundamental step in this process is loss
ofadhesion ofthe cancer cells at the primary site.
Desmoglein (Dsg) and Desmocollin (Dsc) are Desmosomal Cadherins which
represent a novel subfamily ofthe Cadherin cell-cell adhesion molecules.They may
serve as tumour and metastatic supresser molecules. The aim ofthis study was to
determine the role of Desmoglein 2 (Dsg2) in cell adhesion, invasion and
metastasis.
The human breast cancer cell lines MDA MB 231 , MCF 7 and BT 474 were
used. The expression of .Dsg2 was demonstrated with Westem blotting and
Immunocytochemistry.Cell aggregation and invasion was demonstrated with cell-
cell aggregation and in-vitro Matrigel invasion assays. Cell migration was assessed
using Colloidal gold phagokinetic tracking. We compared the breast cancer cells
alone and those treated with a Monoclonal antibody (Mab) to Dsg2.
The mean aggregation index (MAI - mean ± standard deviation )was calculated
over certain time intervals as shown in the table below.
TIME (minutes) after antibody addition 30 60
MDA cells alone *0.67±0.14 *0.78±0.08
MDA + Dsg2 antibody *0.06±0.32 *0.13±0.69
BT474 cells alone *0.69±0.9 *0.8+0.14
BT474 + Dsg2 antibody *-0.71±1. *-0.01±0.81
MCF 7 cells alone *0.58±0.2 *0.69±0.13
MCF 7 + Dsg2 antibody *0.1±0.5 *0.29±0.46
* p< 0.05 Wilcoxon Signed Rank Test.
All cells were invasive into the synthetic basement membrane (Matrigel ) and
the invasive potential was increased when Dsg2 was blocked with antibody. Cell
migration in colloidal gold was also increased in Mab treated cells.
We conclude that Dsg2 is one factor which regulates cell-cell aggregation and
in-vitro invasion of human breast cancer cells. It is proposed that this adhesion
molecule may have an imnportant role in the regulation ofinvasion and metastasis in
patients with breast cancer.
2.4
GAP JUNCTIONAL COMMUNICATION AND THE TYROSINE
2.~4 PHOSPHORYLATION OF CONNEXIN 43 IN THE INTERACTION
BETWEEN BREAST CANCER AND ENDOTHELIAL CELLS. J Cai, W G Jiang,and R E
Mansel. University Department ofSurgery, University ofWales College ofMedicine, Cardiff,
CF4 4XN
Gap junctions play critical roles in maintaining the functional integrity of organs
and tissues. Abnormal gap junction communication (GJC) has been associated with
the process of carcinogenesis. We investigated the the role of endothelial cell GJC
and connexin 43 (Cx43), the main gapjunction protein in these cells, during tumour
cell extravasation.
Breast cancer cells, MDA MB231, were transferred onto confluent monolayers of
human endothelial cells, ECV304. Junctional communication was determined by the
ability of Lucifer Yellow-loaded cells to transfer the dye to neighbouring cells.
Tumour-endothelial interaction was assessed by 1,1'-dioctadecyl-3,3,3',3'-
tetramethylindocarbocyanine perchlorate (DII). Connexin 43 expression and tyrosine
phosphorylation were measured by immunoprecipitation and Western blotting.
Co-culturing ofECV304 with MDA MB231 resulted in a rapid and transient loss
ofcommuniction competence ofECV304 (shown in the table are number ofpositive
endothelial cells transferred with Lucifer yellow, * vs control by Mann-Whitney U
test). The results clearly demonstrated that ECV304 cell communication was
profoundly inhibited within 5 min.
Time (mins) Positive ECV304 cells p value*
0 28.6±1.1 -
5 8.8±0.6 0.01
15 14.4±1.5 0.01
30 16.8±1.0 0.01
60 20.7±1.4 0.01
120 28.7±0.5 0.7
The communication was almost fully restored after 2 h of co-culture with MDA
MB231. Addition of tumour cells showed an increase in the tyrosine
phosphorylation of CX43 protein as revealed by immunoprecipitation and Westem
blotting. This pattern was similar to the loss and the recovery ofGJC in ECV304 as
determined by dye transfer.
We conclude that interaction of tumour cells with endothelial cells effectively
inhibits GJC of endothelial cells, which is attributed to the increased tyrosine
phosphorylation ofconnexin 43. This may contribute to the extravasation oftumour
cells from the circulation, an essential step in the establishment ofmetastasis.8 Oral Presentations
2 . 5 ADHESION OF THREE BREAST CANCER CELL LINES
TO HUMAN UMBILICAL VEIN (HUVEC) AND HUMAN
BONE MARROW ENDOTHELIAL CELLS (HBMEC). *AO'Callaghan, LC Masek and JW
Sweetenham. CRC Wessex Medical Oncology Unit. Southampton General Hospital. S016 6YD.
Adhesion of malignant cells to endothelium at distant sites is one of the key events
in metastatic spread. To further understand this process we have examined the
adhesion characteristics ofthree breast cancercell lines (MDA-MB-361, MDA-MB-415
& MCF-7) to HUVEC and HBMEC.
The adhesion molecule phenotype of the 3 cell lines was determined by flow
cytometry. All cell lines were >95% positive for integrin subunits a3, a5, a6 and 31.
Sialyl Lewis X(sLeX) expression was 100%, 30% and 21% respectivelyfor MDA-MB-
415, MDA-MB-361 and MCF-7.
Adhesion to endothelialmonolayers was examined in a 96-wellfluorescence adhesion
assay system. Single cell suspensions of breast cancer cells were stained with the
fluorescent PKH2 vital membrane dye. 104 cells/well were allowed to adhere to
endothelial cells forspecified times. Fluorescence intensity before and after washing
to remove non-adherent cells was measured using a Cytofluor II fluorescence plate
reader and adherence calculated. For antibody blockade, cells ormonolayers were
preincubated with monoclonal antibodies for 30 minutes, with antibodies remaining
throughout the adhesion period.
Only MDA-MB-415 showed a significant increase in adhesion (two-fold) to activated
HUVEC above resting HUVEC. Adhesion to HBMEC was similarto activated and non-
activated monolayers for all 3 cell lines. Pre-incubation of MDA-MB415 with anti-
sialyl Lewis X or activated HUVEC with anti-E-selectin abrogated the effect of
activation of the monolayer. These antibodies had no effect on adhesion of this cell
line to HBMEC or on either ofthe other cell lines to HUVEC or HBMEC. Expression
of sLeX predicts for increased adhesion to activated HUVEC, mediated by the E-
selectin-sLeX receptor-ligand pair but this mechanism is not used in HBMEC
adhesion.
Incubation of the cell lines with antibodies to integrin subunits a5and 31 caused a
substantial reduction in adhesion of MCF-7 (50 & 52%) and MDA-MB-361(35 & 46%)
to HBMEC. There was no effect on adhesion of MDA-MB-415 to HBMEC. These
antibodies had a detectable but less marked effect on adhesion of all three cell lines
to HUVEC.
We suggest that the integrin a501, is an important mediator of breast cancer cell
adhesion to human bone marrow endothelium.
2.7 RETINOID MODULATION OF MELANOMA CELL
LYSIS BY LYMPHOKINE ACTIVATED KILLER CELLS
AND THE ROLE OF SOLUBLE INTERCELLULAR ADHESION MOLECULE-1
C.L. Alexander, M. Edward and R.M. MacKie, Department of Dermatology,
University ofGlasgow, Glasgow G128QQ.
Intercellular adhesion molecule-I (ICAM-1, CD54) exists as a soluble form (sICAM-
1) in addition to its membrane associated form found on the surface of tumour cells.
sICAM-1 has the ability to bind lymphocyte function associated antigen-I (LFA-1,
CDI1 a/CD18) present on the lymphocyte surface thereby blocking the binding site of
LFA-1 for membrane ICAM-1 on tumour cell surfaces. This is thought to be one
possible mechanism as to how tumour cells evade immunosurveilance. This study
investigates the production ofsICAM-1 from the A375 and C8161 human melanoma
cell-lines pretreated for 4 days with 10-M retinoic acid (RA) and the immunological
consequenses of the interaction of sICAM-1 with IL2 activated peripheral blood
lymphocytes (PBL). The expression of sICAM-1 within cell-free supernatant,
collected over a 4 day period, was determined using an ELISA. Results showed the
A375 cells secreted basal ICAM-1 levels of 40.62fg/cell whereas the C8161 cells
secreted lower basal levels of26.03fg sICAM-ikell. After 4 days pretreatment with
10-M RA, sICAM-1 levels were raised to 51.94fg/cell in the A375 cells yet remained
unaltered in the C8161 cell-line. The immunomodulatory effects of sICAM-1 were
investigated by the addition of sICAM-1 to cytotoxicity assays. IL2 activated/non-
activated PBL were added to chromium-51 labelled tumour cells at ratios rangtng
from 1:1 to 80:1, with the addition of sICAM-1 at the 5:1 and 40:1 ratios. In the
A375 cell-line, 1O0M RA treatment for 4 days did not alter the susceptibility of the
tumour cells to lysis by the PBL and addition ofsICAM-1 at the 40:1 ratio had little
effect on celllysis. However, at the 5:1 ratio, lysis of the control cells by IL2 activated
PBL was reduced from 20.00% to 10.77% and in RA treated cells, from 17.57% to
12.37%. Pretreatment of the C8161 cells with 10-M RA induced an increase in lysis
at the 20:1-80:1 ratios. Lysis of the C8161 cells on addition of sICAM-1 at the 5:1
ratio was reduced in untreated control cells from 27.11% to 18.19% and was reduced
from 22.27% to 3.34% on treatment with RA. At the 40:1 ratio, lysis remained
unaltered in control cells but was decreased in RA treated cells from 74.34% to
25.60%.
Collectively, these results provide evidence that sICAM-1 does appear to partially
block the interaction between PBL and the melanoma cells although the levels of
ICAM-1required to induce this effect are ten times gieater than is secretedfrom the
melanoma cells. Combining these results with additional datafrom our laboratory, it
appears likely that RA treatment of the tumour cells induces changes to several other
molecules possibly involved in the tumour/PBL interaction as well as both membrane
and soluble ICAM-1 expression.
COMBRETASTATIN A-4, AN AGENT THAT DISPLAYS POTENT AND 2 6 SELECTIVE TOXICITY TOWARDS TUMOUR VASCULATURE.
GG Dark'*, SA Hill', VE Pnse', GM Tozer', GR Peittit2, DJ Chaplin'. 'Tumour
Microcirculation Group. Gray Laboratory, Northwood, Middlesex, HA6 2JR, UK, Dept. of Chemistry,
University ofAnzona, USA.
Vasculature is critical to both the survival of a solid tumour mass and its
continued growth. Indeed tumours cannot grow beyond 1-2 mm in diameter without
developing a functional blood supply. Tumour associated endothelium therefore
represents a key target for new approaches to cancer therapy. A number of agents can
produce vascular mediated cell death in experimental and human tumours, however,
only when administered at or close to their maximum tolerated dose (MTD).
Combretastatin A-4 is a constituent of the Zulu medicinal tree Combretum
caffrum, a species indigenous to South Africa. It is a potent cancer cell growth inhibitor
and an effective inhibitor of colchicine binding to tubulin. Combretastatin A-4 and its
more soluble sodium (In) phosphate derivative (prodrug), display concentration-
dependent cytotoxicity against a variety ofhuman tumour cell lines, but have enhanced
selective toxicity towards tumour associated and proliferating endothelium, when
assessed in vitro by a viable cell quantitative assay. In contrast, quiescent endothelium
is quite resistant to the effects ofthese agents.
In view of this selective action against tumour associated endothelium, vascular
studies were performed in experimental and human breast cancer models in vivo.
Histology of a variety of human xenografts and murine transplants indicated extensive
haemorrhagic necrosis at 24 hours following the systemic administration of a single
dose of combretastatin A-4 prodrug at 100 mg-kg-'. Despite the profound vascular
shutdown in the tumours, there was no evidence of morbidity, nor action against non-
tumour tissue. Quantitative assessment of the selective and rapid shutdown in tumour
blood perfusion, was demonstrated using a fluorescent vascular perfusion marker,
which indicates a reduction in functional vascular volume of 93% at 6 hours following
drug administration, with persistence even after 18 hours. There was no corresponding
reduction in normal tissue. Following infusion of combretastatin A-4 prodrug into
isolated rat tumours, a 3-4 fold increase in vascular resistance, consistent with a similar
reduction in blood flow, is evident within 20 minutes. No effect is observed if this
solution is infused into the normal hindlimb, indicating the selective nature of these
vascular effects.
These studies have identified combretastatin A-4 and its soluble prodrug as
agents that can elicit selective effects against proliferating endothelial cells in vitro, and
induce rapid vascular shutdown within tumours in vivo, at doses <10% of the MTD.
These selective actions against tumour vasculature, and the prodrug's broad therapeutic
window without morbidity, demonstrate theexciting clinical potential ofthese drugs.
2.8 ROLE OF bFIBROBLAST GROWTH FACTOR IN 2.8 PPNET'sANDNEUROBLASTOMA*L.Sturla,I.Lewisand
S.A.Burchill.Cancer Research Unit, St James University Hospital, LEEDS LS9 7TF.
Peripheral primitive neuroectodermal tumours (pPNETs) and neuroblastoma are
common solid tumours of childhood, thought to arise following growth arrest of
neural crest cellsduringdevelopment.Nerve growth factor (NGF) and basic fibroblast
growth factor (bPGF) have both been implicated in commitment to a neuronal
phenotype'. We have previously demonstrated NGF and its receptors to be important
in the regulation of neuroblastoma cell growth and differentiation2, but not in
pPNETs. In this study we have examined the effect of bFGF on cell growth and
differentiation in pPNET (TC-32 and RDES) and neuroblastoma (IMR-32 and SK-N-
SH) cells. Proliferation was measured by bromodeoxyuridine incorporation and cell
number using a haemocytometer. Cell phenotype was analysed by Westem blot and
morphology. Effect of bFGF on growth of cell lines in soft agar was also examined.
bFGF(5-8Ong/ml)decreasedincorporationofbromodeoxyuridineinpPNETcellsafter
exposure for 48h. bFGF-induced growth inhibition was accompanied by a decrease
in expression of neurofilament protein and loss of neuronal morphology. Cells lost
their polarphenotype andbecame flattened with multiple short processes. This change
in phenotype was reversible when bFGF was removed. Both pPNET cell lines grew
well in soft agar, colony size and number was reduced in the presence of bPGF
(20ng/ml). In contrast, bFGF increased bromodeoxyuridine incorporation and growth
ofboth neuroblastoma cell lines. bFGF had no effect onmorphology or neurofilament
expression in these cells after exposure for 4 days. Treatment of the IMR-32 but not
SK-N-SH cells for 48h induced the cells to pile up, suggesting bFGF may induce a
more transformed phenotype in the N-myc amplified IMR-32 cells. SK-N-SH cells
did not grow in soft agar, in the absence or presence ofbFGF. However, the IMR-32
cells grew in soft agar and treatment with bFGF (20ng/ml) induced a two-fold
increase inboth colony number and size.
In summary, bFGF decreased proliferation and growth ofpPNET cells on plastic and
in soft agar. This was accompanied by differentiation into a less neuronal phenotype.
In contrast, bFGF increased proliferation and growthof neuroblastoma cells. These
results suggest bPGP-induced withdrawal of pPNET cells fromthe cell cycle may
influence the specification of cell phenotype, and may provide a mechanism for
decreasing growth of these tumour cells. These effects support the hypothesis
pPNET's and neuroblastomas may have derived from differentneural cell progenitors.
1. Anderson DJ.(1993). Ann. Rev. Neurosci., 16:129-158.
2. Burchill SA, Berry PA and Lewis IJ.(1995). J. NeuroL Sci., 133:3-10.Oral Presentations 9
3.1 A RANDOMISED PLACEBO CONTROLLED TRIAL
3 1 OF THE EFFECTS OF MORPHINE-3 AND -6-
GLUCURONIDE ON RESPIRATORY CONTROL AND ANALGESIA.
Richard TPenson*, Simon P Joel, Krishna Bakhshi, Simon J Clark, Richard M
Langford and Maurice L Slevin. ICRF Department of Medical Oncology and
Anaesthetics, St Bartholomew's Hospital, London, UK
Recent reports suggest that morphine-3-glucuronide (M3G) may functionally
antagonise the respiratory depressant and analgesic actions of morphine (M)
and morphine-6-glucuronide (M6G). To investigate this we have conducted a
randomised, double-blind, crossover, placebo controlled study in ten healthy
volunteers. The study had six arms; placebo (P), M 1Omg/70kg, M6G
3.3mg/70kg, M3G 30.6mg/70kg, M3G with M at the above doses and M3G with
M6G at the above doses.Analgesia, assessed using the sub-maximal ischaemic
pain model, and toxicity were measured by numerical and visual analogue
scales. Respiratory parameters and response to 5% CO2 challenge were
assessed by spirometry and mass spectroscopy. Estimation of PaCO2 was by
earlobe blood gas analysis.
M6G and M produced significant pain relief compared to P, (pain relief AUC M
vs P p<0.001, M6 vs P p=0.033), although pain relief after M6 was less than
after M (AUC 4.21 vs 5.63, p=0.009). M3G was not different from P (p=0.26).
Pain relief AUC for M and M6G were not significantly altered by M3G (M vs
M+M3G, p=0.59, M6 vs M6G+M3G, p=0.28). Dysphoria, sedation and nausea
were similar after M and M6G. Significant and similar dysphoria occurred
whenever an agonist was administered but was absent with M3G or placebo
(p<0.003). Ventilation (min-' +SD) following 10mins C02 was; P 15.6(±4.7), M3G
15.0(+3.8), M 11.2(±4.9), M6G 12.7(±4.1), M+M3G 11.5(±3.0) and M6G+M3G
11.8(±3.9). C02 challenge caused significantly less respiratory drive in the
presence of an agonist (ANOVA p=0.003), an effect that was not reversed by
M3G (M6GvsM6G+M3G, p=0.35, MvsM+M3G p=0.83). These data were
supported by measurements ofresting FeCO2 and ear lobe blood gases.
This study is the first placebo controlled trial of the analgesic effects of M6G in
man. The data suggest an analgesic potency ratio for M6G:M of around 2:1.
This is the first time that the pharmacology of M3G has been examined in
isolation in man. M3G appears devoid of significant activity and does not, in
these circumstances, appear to antagonise M6G ormorphine.
3.3 PHASE I STUDY OFTHYMITAQ1MIN CHILDREN WITH
ADVANCED CANCER. EstlinEJ',2, PinkertonCR', AblettS',
GowingR', LashfordL', MorlandB', McDowellH', LewisLI', KohlerJ', Newell
DR24, TaylorGA2,BoddyAV', JohnstonA3,ClendenninN3, PearsonADJ'. On behalf
ofthe UnitedKingdomChildrens CancerStudyGroup', Cancer ResearchUnit,Universityof
Newcastle uponTyne Agouron Pharmaceuticals Inc, SanDiego, U.S.A. and the CancerResearch
Campaign4.
THYMITAQT (AG337) is a non-classical inhibitor ofthymidylate
synthase, the terminal enzyme involved in the de-novo synthesis of
thymidylate. Ultimately, the agent may have a role in thetherapy of
tumours responsive to methotrexate. A multicentre Phase I study of
THYMITAQTht, administered as a continuous 5 day intravenous infusion
every 28days via a central line, has commenced for children with
advanced cancer. Threepatients (pts) were treated at480mg/m2/24hrs
(free base). There were no acute toxicities seen andsteady stateplasma
levels of5-7pg/ml (mean AUC =45mg/ml.min; range41-52) were
achieved. Sixpts have been treated atthe second dose level of
620mg/m2/24hrs (free base), and 3 pts are evaluable fortoxicity. No
dose limiting toxicities have beenobserved. In 1 pt, CTC Grade 2 oral
mucositis was seen, and in a second pt, Grade 3 mucositis (affecting the
uppergastrointestinal tract) and Grade 3 neutropenia and
thrombocytopenia were observed. In bothpatients, all toxicities had
resolvedby day 12. Pharmacokinetic analyses infivepatients at the
second dose level have beenperformed, and steady stateplasma levels of
6-10,tg/ml(mean AUC = 54mg/ml.min; range 41 -69) were achieved.
At both dose levels,THYMITAQT was rapidly cleared from theplasma
at the end ofthe infusion, (elimiation half-life = 1.2 -2.6 hours). No
responses have beenobserved, although in 2 pts with acute lymphoblastic
leukaemia atthe first doselevel, a 50% reduction in theperipheral blast
count was found at the end ofthe 5 day infusion. Thepharnacokinetic
results are inkeeping with the findings from the adult Phase I study of
THYMITAQTmgiven as a continuous 5 day infusion. THYMITAQTm
has been sucessfully administered on an outpatient basis, and multicentre
pharmacokinetics have been possible The third dose level of 768
mg/m2/24hrs (free base) has opened, and recruitment tothe study
continues.
PHARMACODYNAMIC STUDIES OF THE BIOLOGICAL
3,2 EFFECT OF THYMIDYLATE SYNTHASE INHIBITORS:
FROM LABORATORY TO CLINIC. D Farrugia*', K Danenberg2, D
Cunningham', R MetzgerK, P Danenberg2, HJ Lenz , F Mitchell', GW Aherne',
D MacVicar', K McCarthy', A Norman', AL Jackman'. 'Inst. of Cancer
Research and Royal Marsden Trust, Surrey. 2USC, Los Angeles, CA 90033.
In vitro studies with the quinazoline based specific thymidylate synthase (TS)
inhibitor ZD1694 (TomudexTM) in human tumour cell lines have shown
resistance through impaired transport, decreased polyglutamation by down-
regulation of folylpolyglutamyl synthetase (FPGS), and increased TS
expression (Jackman AL, 1995, Br. J. Cancer, 71: 914). In mice, an inter-
strain difference in ZD1694 toxicity is associated with different tissue drug
levels. Following 10 mg/kg daily x 5 days, Balb/c mice lose 25% of baseline
weight compared to 10% in DBA2 mice. Small bowel drug levels on day 5
were 3.2 ± 1.9 nmol/g in Balb/c and 0.9 ± 0.4 nmol/g in DBA2 mice (p=0.0004,
n=3). Clinical studies have reported lower tumour TS expression in responding
advanced gastric and colorectal cancer (CRC) (Johnston P, 1995, Cancer Res.
55:1407). This study examines the correlation between tissue drug retention,
target enzyme expression, and efficacy/toxicity of Tomudex (3 mg/M2 3
weekly), in patients (pts) with metastatic CRC. Pts have pre-treatment (Pre-Rx,
day -1) and post-treatment (Post-Rx, day 5) CT-guided tumour biopsies during
the first Rx course. Same day biopsies of normal rectal or colonic mucosa are
also performed. Pre-Rx measurements consist of tissue levels of FPGS and
TS mRNA (rt-PCR), and immunohistochemistry (IHC) for TS protein (also in
primary tumour) and p53 status. Post-Rx studies include polyyglutamated drug
levels (radioimmunoassay; RIA) and TS protein (IHC). Plasma is collected for
Tomudex (RIA) and deoxyuridine levels (accomp. abstract). Data from the first
7 patients show an 8 and 4-fold variation in TS mRNA levels in tumour (TS/11-
actin ratios 2-17), and bowel (range 3-11) respectively. Tumour FPGS mRNA
varied 35-fold (FPGS/13-actin ratios 16-560) compared to 14-fold (range 26-
368) in bowel. Two thirds of tumours stained positive for p53. Day 5 Tomudex
levels ranged from 0.22 to 0.78 nmol/g in tumour, and 0.06 to 0.2 nmol/g in
bowel. Day 5 tumour/plasma and bowel/plasma drug ratios were high (90 and
70 respectively) with drug still detected in plasma on day 21 (- 2 nM). To date,
4 out of 7 pts have shown disease response, 3 of these in the biopsied site.
There is an indication of greater bowel toxicity in pts with higher bowel drug
levels: grade 0-1 toxicity 0.10 ± 0.05 nmol/g (n=3); grade 2-4: 0.18 ± 0.03
nmol/g (n=4) (p=0.03). Such correlations may in future improve patient
selection and assist dose adjustment. Supported by the Cancer Res.
Campaign and Zeneca Pharmaceuticals.
The pharmacokinetics ofetoposide in combination
3 with cisplatinand carboplatin. H.D. Thomas*,
D.J. Porter, J.Nobbs, M. Highley, F. Chapman, A.H. Calvert, A.V.Boddy
Cancer Research Unit, University ofNewcastle, Newcastle upon Tyne, UK.
Etoposide is frequently combined with eithercisplatin or carboplatin in a
number ofchemotherapy regimens. Studies ofcombinations ofcisplatin or
carboplatin with etoposide in patients with testicular teratoma have shown that,
although both regimens acheive the same percentage response rate, relapse was more
frequent in patients receiving carboplatin (Bajorin, et al. J. Clin. Oncol. 11:598-606
(1993)). As single agent treatments for other tumours, carboplatin and cisplatin have
been shown to be equally effective at equitoxic doses (Taylor, et al. J. Clin. Oncol.
12:2066-2070 (1994)). One explanation for this observation is that either cisplatin or
carboplatin interferes with the pharmacokinetics or pharmacodynamics ofetoposide
(Relling, etal. Clin. Pharmacol. Ther. 56:503-511, (1994), Rodman, et al. J. Clin.
Oncol. 12:2390-2397 (1994)). The objective ofthis study was to determine the effect
ofconcurrent administration ofcarboplatin or cisplatin upon the pharmacokinetics of
etoposide.
Patients with solid tumours, for whom a combination ofetoposide with a
platinum drug was appropriate, were studied. All patients had normal liver and renal
function, as defined by standard tests. Patients were treated with etoposide 100mg/M2
as a 60 mininfusion on 3 consecutive days. On day 2, patients were randomised to
receive either carboplatin at a dose based on renal function to achieve an AUC of
Smg/ml.min, or 100mg/M2 cisplatin with saline diuresis. Patients were crossed over
to the otherplatinum drug for the second course. Blood samples were collected
throughoutdays 1-3 for both courses. The plasma concentrations ofetoposide were
assayed by HPLC. The AUC ofetoposide on each day was calculated using the
trapezoidal rule.
Ten patients have been studied so far. Ofthese 7 recieved both
combinations, 2 recieved only the cisplatin arm and I recieved only the carboplatin
arm. The administration ofcisplatin did not cause a significant change in the AUC of
etoposide, comparing day 2 to day 1. However, the AUC ofetoposide on day 2 was
significantly increased (median 16%, range -2 to 41%) when carboplatin was co-
administered (p=0.007, paired t-test). This effect was reversed on day 3, when the
AUC was not different to that on day 1. The order ofstudy ofthe platinum drugs
made no difference to the results. Investigations are continuing into the mechanism
of this apparent interaction.10 Oral Presentations
3 5 FIBROBLAST GROWTH FAC'TOR RECEPTOR FOUR EXPRESSION
IS INCREASED IN HUMAN COLORECTAL CANCER
A. C. R. B rns . A. C. Gough', W. R. Rocie2 and J. N. Prinirose'. University Surgical nlit anid
2I'niversusy Pathology. Sotithaiiiptoni Genieral Hospital, Sothatlaptoi S016 6YD
The Fibroblast Growth Factor (FGF) Family which have been implicated in
tumourigenesis act via four tyrosine kinase cell surface receptors (FGFR 1 - 4).
Basic FGF (FGF 2) markedly stimulates the growth of human colorectal cancer
cell lines, and in solid colorectal tumours has been immunolocalised to
carcinoma cells and extracellular matrix components.
The aim of this studv was to analyse the expression of FGFR 1 4 at the
niRNA and protein level in normal and malignant colorectal tissue Total
niRNA was extracted from 22 colorectal cancer / mucosa paired samples
previously snap frozen in liquid nitrogen. RT PCR was performed and the
products resolved by polyacrylamide gel electrophoresis and their nature
confirmed by cloning and sequencing. To determine the cellular distribution of
FGFR, immunohistochemistry was carried out on paraffin embedded colorectal
tumours using the streptavidin biotin complex immunoperoxidase technique
with antibodies (Santa Cruz Biotechnology) specific for the carboxytermini
of FGFR 1-4.
FGFR 1 4 was expressed in both normal mucosa and tumour specimens:
FGFR Mucosa (n = 22) Tumour (n = 22)
86% 82%
2 820% 91%
3 91% 95%
4 82% 100%
The increased expression in tumour compared to the matched mucosa was
statistically significant for FGFR 4 ( p < 0.001) but not for the other FGFR.
FGFR 1 4 was immunolocalised to the carcinoma cells in addition to normal
colonic glands. microvasculature. fibroblasts and smooth muscle.
The apparent up regulation of FGFR 4 suggests that this receptor may play
a role in colorectal tumour development.
3. ANALYSIS OF MICROSATELLITE INSTABILITY IN
MULTIPLE TUMORS OF THE LARGE BOWEL.
M.G.Tamassia, G.Rossi, L.Roncucci, M.Pedroni, P.Benatti, C.Di Gregorio,
F.Vaccina, R.Fante, M.Ghidoni, A.Percesepe, L.Losi, S.De Pietri, M.Ponz de Leon.
Dipartimenti di Medicina Interna e di Scienze Morfologiche e Medico Legali,
UniversitA di Modena.
Synchronous or metachronous are observed in about 4-10% of all patients with
colorectal carcinoma. Multiple colorectal neoplasms occur significantly more often
in patient with Lynch Syndrome (HNPCC) than in general population. Replication
errors (RER), expressed as DNA instability in simple repeated nucleotides of 14
base pairs (microsatellites), are frequent in colorectal cancer developing in families
with HNPCC, but have been also demonstrated in sporadic colon cancer. We
analyses 65 neoplasms from 31 patients with multiple tumors of the large bowel.
This sample was selected from the 1,298 registered individuals of a specialized
colorectal cancer registry, instituted in our Health Care District. Aim of our study
was to assess the frequency ofmicrosatellite instability and its biological significance
in multiple tumors. RER were detected by analysis of the microsatellites which seem
particularly prone to insertions or deletions ofbaseu in hereditary colorectal tumors.
DNA was extracted from normal and cancerous forinalin-fixed tissue and(amplified
by PCR for 35-40 cycles. PCR products were analysed on 6% denaturating
polyacrilamide sequencing gel. Tumors with RERs in at least one of five
microsatellite loci (D2S123, D17S787, D18S57, BAT40, D9S178) were defined as
RER+. We studied 38 synchronous (S) and 27 metachronous (M) tumors. RER
phenotype was observed in 13 neoplasms (out of 65, 20%); among these, 11 were S
(out of 38, 29%/) and 2 M (out of 27, 7%/6). A fraction of these neoplasms was from
HNPCC patients: 9S and8 M. RER positivity in HNPCC multiple tumors was 47%
(8 out of 17), 77% in S (7 tumors of 9), and 12.5% in M (I tumor of 8). The
percentage of RER+ in S and M sporadic tumors was 13.8% (4 tumors of 29) and
5% (one of 19) respectively. Conclusions: the RER+ phenotype seems infrequent in
multiple colorectal malignancies (20% of the cases), at least with the most
commonly used primers. However, the expression of the RER+ phenotype seem
closely associated with HNPCC; thus, we confirm that the RER assay can be of help
in identifying Lynch syndrome in the general population.
BCL-2, PLATELET-DERIVED ENDOTHELIAL
3.6 CELL GROWTH FACTOR (PD-ECGF) AND
TUMOURAL ANGIOGENESIS IN NON-SMALL CELL
LUNG CANCER (NSCLC). KJ O'Byrne*1, MI Koukourakisl' 3,
A Giatromanolaki2' 3, KC Gatter2 and AL Harrisl. ICRF
Medical Oncology Unitl and Dept. ofCellular Science2, Oxford
Radcliffe Hospital, U.K. and Dept. of Radiotherapy and
Oncology, University Hospital ofIraklion, Greece3.
Angiogenesis, the formation of new blood vessels, is essential
for tumour growth beyond 1 - 2mm in diameter and plays a
key role in tumour metastasis. Angiogenesis, assessed by
tumour blood vessel counts, is an important prognostic factor
in a number of solid tumours including NSCLC. Bcl-2
expression is associated with an improved prognosis and is
inversely related to angiogenesis in NSCLC. PD-ECGF
overexpression is seen in 25% of NSCLC patients and is
positively correlated with angiogenesis.
134 surgical specimens from patients with operable T1,2-NO,1
staged NSCLC were examined for vascular grade (high vs low)
immunohistochemically using the anti-CD31 antibody, JC-70.
Bcl-2 and PD-ECGF (positive vs negative) immunoreactivity
was analysed using the monoclonal antibodies clone 100 and
P-GF.44C respectively.
Bcl-2 expression correlated with low vascular grade tumours
(p=0.03) and negative PD-ECGF expression (p=0.03). 3/27
(11%) bcl-2 positive cases had high vascular grade tumours vs
34/107 (32%) of bcl-2 negative cases. 20/35 (57%) bcl-2
negative cases expressing PD-ECGF were of high vascular
grade vs 15/72 (20%) bcl-2 and PD-ECGF negative cases
(p<0.0003). Positive PD-ECGF expression is associated with a
poor prognosis (p=_0.01). This work supports our previous
contention that bcl-2 may be a suppressor of tumour
angiogenesis and correlates with low PD-ECGF gene
expression. The results also suggest the involvement of an
oncogene that switches on angiogenesis and confers poor
prognosis in caseswith absent bcl-2 or PD-ECGF expression.
GERMLINE MUTATIONS OFhMSH2 AND hMLHI GENES 3.8 IN LYNCH SYNDROME.
A.Viel, M.Genuardi, A.Bellacosa, E.Capozzi, M.Anti, M.Ponz de Leon, M.Pedroni.
M.G.Tamassia, L.Roncucci, P.Benatti, A.Percesepe, G.Neri.
Istituto di Genetica Medica, Universita Cattolica, Roma; CentroOncologico Aviano,
Dipartimento di Medicina Interna, Universita di Modena, Italy.
Lynch Syndrome (or HNPCC, for Hereditary Nonpolyposis Colorectal Cancer) is an
inherited disease which accounts for 3-5% of all colorectal cancer (CRC) burden.
HNPCC diagnosis is based on the so-called "Amsterdam Criteria" requiring the
presence, in a family, ofthree or more relatives with verified CRC in two successive
generations, one of whom should be first-degree relative with the other two, and at
least one case diagnosed before age 50. The molecular basis of HNPCC has recently
been elucidated by identifying the role of defects of DNA mismatch repair genes
called hMSH2, hMLHl, hPMSI, hPMS2, from the homologous bacterial genes
involved in the maintainance of DNA integrity during cell replication. We have
investigated type and frequency of mutations at the hMSH2 and hMLHI loci in a
series of 17 Italian HNPCC families. The methods used for mutation analysis -
carried out on DNA extracted from peripheral white blood cells - were: RT-PCR on
cDNA for the detection of gross rearrangements, and SSCP (on either cDNA or
genomic DNA) followed by direct sequencing, for detecting point mutations.
Overall, 9 mutations were identified: 6 were predicted to inactivate mismatch repair
function while 3 were considered polymorphisms.The mutated gene was hMSH2 in
2 families and hMLHl in 4. Four mutations have not been previously reported; these
are: 1) a point mutation at the splice donor site in intron 17 of hMLHl, which causes
skipping of exon 17 in mRNA; 2) a deletion of exon 3 from hMLHl mRNA, not
associated with sequence changes in the exon itself or in intron-exon borders, 3) a 4-
nucleotide deletion in exon 7 of hMSH2, causing premature termination of the
reading frame, and 4) a nonsense mutation, occurred at hMLHI codon 301 as a
consequence ofa CAG-+TAG transition. The other mutations identified were a 3 bp
deletion removing a lysine from a stretch of 3 repeated lysines encoded at position
616-618 of hMLHI, and a GTA-+GTT transversion occurring at the splice donor
site in intron 5, which causes a deletion of exon 5 of hMSH2. Conclusions: the
overall mutation frequency at either of the two loci was 35.3% of all investigated
families; four of the six mutations detected in our study were not previously
described. Gene carrier test, in asymptomatic individuals, is now feasible in the 6
families where a pathogenetic mutation has been identified.Oral Presentations 11
4.1 THE ACTIVITY OF SN-38 IN P53 WILD-TYPE AND
MUTANT COLORECTAL CANCER CELL LINES.
Robert H. te Poele, Maurice L. Slevin, Simon P. Joel. ICRF Department of
Medical Oncology, St. Bartholomew's Hospital, London.
SN-38 is the active metabolite of the topoisomerase inhibitor CPT-11. We
have investigated the effect of SN-38 concentration, exposure duration and
drug AUC on activity and cell cycle distribution in HT29 (mut p53) and LS174T
(wt p53) human colorectal cancer cell lines. Cells were exposed to SN-38 (0-
100 Tig/mI) for 1-7 days. Percentage survival was assessed by the MTT
assay, and cell cycle distribution, including apoptotic cells, was determined by
flow cytometry. In HT29 cells arrest in G2 developed within 24h of exposure,
during which Gi was rapidly emptied at concentrations > 10 slg/ml, with
accumulation continuing up to 48h. The extent of accumulation increased to a
maximum at 20 Tlg/ml (87.7 + 2.6%) and declined at higher concentrations.
After 48 h release from G2 and concomitant increase in apoptotic cells (up to
83.2 + 2.8%) and decrease in cell survival (down to 4.5 ± 1.4%) was also
concentration dependent. There was poor correlation between AUC and
survival or apoptosis (R2 = 0.45 and 0.50 respectively). For incubations with
the same AUC survival was significantly lower for more prolonged exposures
to lower concentrations (i.e. for an AUC of 1440 Tg/ml.h survival at 48 h x 30
ng/ml = 108.5 + 10.6%, 72 h x 20sg/ml = 83.2 + 11.6%, 144 h x10,qg/ml =
43.5 + 12.4%, p= 0.0122), suggesting a possible schedule effect. In LS174T
cells arrest in both Gl and G2 occurred at all concentrations, and in S at
concentrations >20 qg/ml, and was associated with increased p53
(determined by flow cytometric analysis using D07 Ab) in each case. The
onset of apoptosis and the decrease in survival developed within 24h at all
concentrations. Apoptosis and decrease in survival continued up to 96 h after
which the effect reached a plateau. Thereafter, surviving cells (25-50%)
showed continued arrest in Gl, G2 and S at higher concentrations, again
associated with increased levels of p53. These data suggest that increased
sensitivity to lower concentrations of SN-38 and cytotoxicity in Gl is
associated with expression of wt p53 and that lack of wt p53 results in delayed
cytotoxicity. In LS174T cells with wt p53 pulsed delivery may prove more
effective by allowing arrested cells to return to cycle, whereas in HT29 cells
with mut p53 continued exposure is effective.
4.3 RESIDUAL DNA DAMAGE AS A RAPID
PREDICTIVE ASSAY OF RADIOSENSITIVITY,
A.E. Kiltie*', C.J. Orton', A. Ryan2, B. Marples', C.M.L. West'.
Dept. OfExperimental Radiation Oncology, 2 University ofManchester
Department ofOncology, Paterson Institute for Cancer Research, Christie
Hospital NHS Trust, Manchester M20 4BX.
It has been shown that fibroblast clonogenic survival correlates with late
normal tissue responses in cancer patients treated with radiotherapy. However,
clonogenic assays take too long to have practical application in routine testing
ofpre-radiotherapy patients. Residual DNA damage assays using pulsed field
gel electrophoresis (PFGE) are more rapid, and a correlation with clonogenic
survival has been shown to exist over a wide range ofSF2 values.
A study was made ofthe relationship between residual DNA damage and
clonogenic measurements ofradiosensitivity in fibroblasts from pre-treatment
cervix cancer patients and two radiosensitive skin fibroblast cell strains.
Residual DNA damage was measured using PFGE after irradiating
radiolabelled, plateau-phase cells at 37°C and allowing 24 hours for repair.
DNA damage was expressed both in terms ofthe residual damage slope (60
150 Gy) and the fraction ofactivity released (FAR) following 150 Gy.
There was a 2.2-fold difference in surviving fraction at 2 Gy (SF2) for the
vaginal fibroblasts (0.15 to 0.32) compared to a 4.0-fold difference in residual
DNA damage slope. When the two radiosensitive cell strains were included,
residual damage slope correlated with a (r=0.82, p=0.002), D bar (r=-0.91,
p<0.001) and SF2 (p=-0.79, p=0.004), and for the vaginal fibroblasts alone the
correlations were a: r=0.66, p=0.053, D bar: r=-0.83, p=0.006 and SF2: r=
-0.63, p=0.07. When residual damage was expressed as FAR at 150 Gy, then
for all cell strains the correlations were a: r=0.78. p=0.004, D bar: r=-0.86.
p=0.00I, and SF2: r=-0.78, p=0.004, and.for the vaginal fibroblast strains
alone the correlations were a: r=0.60. p=0.088, D bar: r-0.75, p=0.02, and
SF2: r-0.62, p=0.077.
This study demonstrates a correlation between residual DNA damage and
clonogenic survival for fibroblasts from pre-treatment cervix cancer patients
suggesting that residual DNA damage as measured using PFGE may be useful
as a rapid predictive assay ofnormal cell intrinsic radiosensitivity.
4 ,2
FORMATION AND REPAIR OF SEQUENCE
SPECIFIC TALLIMUSTINE ADDUCTS AT NUCLEOTIDE
RESOLUTION IN HUMAN CELLS. Grimaldi, K.A.*I, Beccaglia, P.A2,
D'Incalci, M.2 and Hartley J.A.1 'CRC Drug DNA Interactions Research
Group, Dept. of Oncology, University College London Medical School,
London. WIP 8BT 21stituto di Ricerche Mario Negri, via Eritrea 32, 20137
Milano, Italy.
Tallimustine is a benzoyl'mustard derivative of distamycin A which is
cytotoxic and has anti-tumour activity. Following non-covalent binding at
AT-rich sequences in the minor groove of DNA it alkylates with high
sequence specificty and in plasmid DNA, naked genomic DNA and in treated
human cells it has been shown to form adducts preferentially at 5'-TITGA
and 5'-'TTTGG sequences in a region of the TOPO IIa gene. Using single
strand ligation PCR the current study investigated damage and repair of
DNA, at the nucleotide.level, after tallimustine treatment of Li-Fraumeni
Syndrome derived cells (LFS-087) containing a homozygous P53 mutation. A
500bp promoter region of the human N-ras gene was chosen for study-it
contains two 5-'l-lTGA sites on the non-transcribed strand and none on the
transcribed strand. After treatment with 2 - 20 gM tallimustine for 2 hours
there was no detectable adduct formation on the transcribed strand. On the
non-transcribed strand there was only one major adduct at a 5'-TTTT'GA site
and minor adducts (approx. 6-fold less frequent) were detected at the other 5'-
TTTTGA site and at 5'-GTTTGA & 5'-TATTGA sequences. In naked
genomic DNA the adduct pattern was essentially the same except that there
was some non-specific binding to guanines at high doses which was seen in
both strands. Sequencing of the gene in this region confirmed that the
sequence in the LFS cells was identical to the published sequence. After
incubation in drug free medium for 24 hours no repair of any adduct was
detected at all doses tested, in fact the intensity of the individual adducts
increased during this period. These studies have therefore confirmed the high
sequence specificity of tallimustine in human cells. The different affinity for
the two 5'-TTTIGA sites is probably due to sequence context rather than
intracellular protein-DNA structural features since the same pattern was
observed in cells and naked DNA. No tallimustine lesions were repaired in
these P53 mutant LFS cells despite the fact that they were capable of
repairing damage caused by cisplatin. The observed increase in adduct
intensity may be due to slow formation of the covalent link with DNA.
4 14 DNA-TARGETED THERAPY: DIFFERENTIAL
CYTOTOXICITY OF ALTERNATIVE
RADIODOANALOGUES OFIUDR TO HUMAN GLIOMA SPHEROIDS. Mairs RJ'
Neshasteh-Riz A2, Wheldon TE'2, Angerson W3, Stanton P3, and OwensJ4. 'Dept. Of
Radiation Oncology, Univ. of Glasgow, Glasgow, G61 1BD, 2Dept. of Clinical Physics,
Western tnfirmary, Glasgow, G11 6NT, 3Dept. of Surgery, Univ.of Glasgow, Royal
Infirmary, G31 2ER, 4Radionuclide Dispensary, Western Infirmary, Glasgow, G11 6NT
Radioiodinated iododeoxyuridine (IUdR) is a novel, cycle-specific agent which has
potential for thetreatment of residual malignant glioma after surgery. Since only
cells in S phase will incorporate IUdR into DNA, a major limitation to this therapy
is proliferative heterogeneity of the targeted, tumour cell population. Using a
clonogenic assay end point, we have compared the toXicities of three
radiodoanalogues of IUdR - [123I]IUdR, [1251]IUdR and [131 ]IUdR - to the human
glioma cell line, UVW, cultured as monolayers in exponential and plateau phase of
growth and as multicellular spheroids. Monolayers treated in exponential growth
phase succumbed most readily to ['251]IUdR (Do = 2.36kBq.ml-t), while ['231]IUdR
and [131I]IUdR were less effective eradicators ofclonogens (Do = 9.75 and 17.11
kBq. mlt' respectively). Plateau phase monolayer cultures were marginally more
susceptible to treatment with [1231]IUdR and ['251]IUdR (40% clonogenic survival)
than [(31I]IUdR (60% clonogenic survival). In contrast, colony formation from
cells derived from glioma spheroids after incubation with 40 kBq.ml-1 of
radiopharmaceutical was inhibited to a greater extent by [tstI]IUdR than by
[123i]iUdR or [125I]IUdR: clonogenic survival values were 17%, 42% and 35%
respectively. It is concluded that IUdR conjugates of the Auger electron emitters
1231 and 125I killed only cells which were in S phase during the period of incubation
with radiopharmaceutical, whereas the superior toxicity to clonogenic cells in
spheroids of [131I]IUdR was due to cross-fire(-irradiation. ['251]IUdR was more
toxic than [t23IlUdR when compared on the basis of administered activity.
However, in terms of number of molecules of radiolabelled drug, [1231]IUdR was
approximately ten times more effective than [1251]IUdR. These findings suggest
that ['3'I]IUdR or combinations of [13'I]IUdR and [1231]IUdR may be more effective
than [1231]IUdR alone for the treatment of residual glioma.12 Oral Presentations
4.5 TAXOL RESISTANCE IN A HUMAN OVARIAN
CARCINOMA CELLLINE OCCURRING VIA A NON
MEMBRANE-MEDIATED MECHANISM.
P.M.Rogers*, S.Y.Sharp and L.R.Kelland. CRC Centre for Cancer Therapeutics atThe
Institute ofCancer Research, Sutton, Surrey, U.K.
Taxol (Paclitaxel) is a novel tubulin-binding antineoplastic agent recommended for
combination with Cisplatin in late stage ovanran cancer.
We have previously reported a taxol-resistant vanrant of the CHI human ovanran
carcinoma cell line and are continuing investigations into its resistance mechanism. Using
96Hr Sulphorhodamine B assays, the CHITaxol' was found to be 12-fold resistant to
taxol and non-cross-resistant to the closely related molecule Taxotere. A trend towards
sensitivity to microtubule depolymerizing agents was also apparent.
The addition of6,M verapamil had no effect on the resistance ofCH Taxol' to taxol and
westem blotting ofmembrane extracts revealed no detectable P-glycoprotein, suggesting
that intracellularfactors, rather than Pgp-mediated drug exclusion are responsible for the
increased resistance. The Multidiug Resistance Associated Protein (MP) was also
undetectable. Using ['H]-taxol, uptake oftaxol by CHI and CHITaxolR was measured,
revealing that at isotoxic concentrations, CHl Taxol' contained 5.6-fold higher taxol
concentration than the parent line, indicating increased tolerance for intracellular taxol.
No significant difference (P>0.05) in the native levels ofGlutathione was found between
CHI and CHI Taxol' and no induction of glutathione by exposure to IOnM taxol was
detected. The doubling time of the parent and resistant cell line was not significantly
different at 28.2hr and 28.7hr respectively. This corresponds with the 24hr exposure at
which taxol cytotoxicity reaches its maximum, all the cells having passed through one
entire cycle. The chromosome number of CHI TaxolR was established and compared to
that ofthe parent line, revealing a 3-fold increase in the proportion of cells containing 80+
chromosomes, possibly indicating an increase in the level of polyploidy in the population.
The resistance ofother cell lines to taxol has been reported to lie at the level of
tubulin, but no difference in the total levels ofboth a- and Il-tubulin was detectable by
western blotting. Resistance mediated via differences in specific tubulin isoforn
expression is a possibility and is currently being investigated.
147 IDENTIFICATION OF DIFFERENTIALLY
EXPRESSED SEQUENCES BY DIFFERENTIAL
DISPLAY RT-PCR IN A HUMAN GASTRIC CARCINOMA CELL
LINE WITH ACQUIRED RESISTANCE TO MITOXANTRONE,
L Hutchinson*1, C Challen2, J Lunec2, J A Hartley1, I CRC Drug-DNA
Interactions Research Group, Department of Oncology, University College
London Medical School, London, WIP 8PT, 2Cancer Research Unit,
University ofNewcastle upon Tyne, NE2 4HH.
The human gastric carcinoma cell line EPG85257P (1) exhibits a high
sensitivity (IC50 0.005lM) to the intercalating anthracendione drug
mitoxantrone. A highly resistant variant EPG85257RNOV has been
established (IC50 70FtM) with an acquired resistance factor of 14000. The
resistance mechanisms have previously been shown to be unrelated to P-
glycoprotein and showed minimal involvement of topoisomerase II.
Differential display RT-PCR has been employed to detect changes in gene
expression between the EPG85257 cell lines. Several reproducible
differentially displayed bands were detected. Further analysis of the genes
displayed was achieved by cloning, sequencing and Northem blotting.
One sequence when searched against Genbank matched racl, a low
molecular weight GTP binding protein in the ras gene family (2). This
approximately 200bp sequence was used to probe mRNA Northerns and
reproducibly showed a 60% reduction of expression in the resistant cell
line. In order to obtain further sequence information the Rapid
Amplification of Complementary Ends (RACE) technique was applied.
Down regulation of this protein in the resistant cell line may be related to
facilitation of exocytosis by reducing the actin cytoskeleton. Vesicles have
been reported previously in this cell line following treatment with
mitoxantrone (1).
A second sequence matched to a transmembrane glycoprotein when
searched against Genbank(3). Northern blotting showed it to be
overexpressed by 56% in the resistant cell line. The full length clone was
obtained and was used as a probe for Northern blotting confirming the
identity ofthe protein. The function of this protein is unknown.
(1) Dietel, M etal Cancer. Res. Q 6100(1990)
(2) Didsbury,J J. Biol. Chem. 2fA 16378 (1989)
(3) Shimada, S CancerResearch 54 3831 (1994)
4 .6 TRANSCRIPTIONAL ACTIVATION OF THE
mdrlb GENE IN RAT MAMMARY
CARCINOMAS THROUGH AN NF-IL-6 LIKE REGULATORY
ELEMENT. F. Zhang, J. Riley, T.W. Gant, MRC Toxicology Unit,
University of Leicester, Lancaster road, Leicester. LE1 9HN
Mammary carcinomas can be quickly and reproducibly induced by the
administration of N-nitroso-N-methylurea to Virgin female rats. We
have demonstrated a specific induction, by up to twenty fold, of mdrlb
gene expression in these tumours (Zhang et al, Lab. Invest 75, 413
(1996)). We investigated the mechanism of increased mdrlb gene
expression. Southern analysis indicated that a gene amplification had
not taken place. Analysis of mdrlb gene transcription rate, by an RT-
PCR based method, revealed an increase in tumour tissue. We
performed gel mobility shift assays on regions of the rat mdrlb
promoter known to be involved in the control of basal transcription in
the liver (Silverman and Hill Mol Car. 13a 50 (1995)), and which
showed homology to footprinting regions in the mouse mdrlb promoter
known to be important in causing elevated transcription of the gene in
mouse hepatomas (Song et al JBC 270, 25468, (1995)). We detected
binding of a mammary tumour specific protein to one of these regions
in the rat mdrlb gene promoter region. Mutation analysis identified the
consensus region as TGnnnATGT. This region is directly adjacent to
one recently identified in the rat as important for mdr gene expression
in a variety of cell lines (Zhou et al, Cell Growth and Diff. 7, 1369
(1996)). We have not yet identified the protein binding to our region
but some homology with the NF-IL-6 binding site (TGnnATGT) is
apparent. This is consistent with our observation of increased
expression of P-glycoprotein, the protein product of the mdr genes,
around areas of necrosis and inflammation, which are known to release
the cytokine IL-6. Additionally, NF-IL-6 is activated by protein kinase
C, and an increase in the expression, and translocation to the plasma
membrane, of these enzymes is often seen in multidrug resistant cells.
4.8 INTERFERON INCREASES ApH OF HT29 TUMOUR
CELLS, A.S.E. Ojugoi.2.3, P.M.J. McSheehy' 0, M.O.
Leach2, I.R. Judson' and J.R. Griffiths', 'CRC Biomedical Magnetic Resonance
Research Group, St. Georges Hospital Medical School, London SW17 ORE and
'CRC Clinical Magnetic Research Group and 'CRC Centre for Cancer
Therapeutics, Royal Marsden NHS Trust, Sutton, Surrey, SM2 5PT.
A useful aid in assessing a tumour's response to radiation or chemotherapy
is pH. McCoy et al., (Brit. J. Can., 72, 905, 1995), demonstrated that 31P
Magnetic Resonance Spectroscopy (MRS), can be used as a non-invasive method
for both extracellular and intracellular pH (pH.., and pHi,) measurements,
whereby the plasma membrane pH gradient (ApH) can be determined. Ladoux
et al., (FEBS Letts., 234, 353, 1990), showed that interferon can activate the
Na+/H+ antiport system in isolated human tumour cells thereby inducing
cytoplasmic alkalinization. The aim of this study was to determine if interferon
affected the pHi., and pH.,, of human HT29 colon tumours in vivo.
Human HT29 cells (106/ml) were injected s.c into the flank of nu/nu mice
(30 g). 31p MRS was performed when tumours reached 0.5-1.5 g. Each mouse
received 50,000 IU of interferon i.p. at 24-30 hr and 2-4 hr before start of MRS
experiments. The 31p pH,,, marker, 3-aminopropylphosphonate (3-APP), was
injected i.p. (11 mmol/kg) - 20 min prior to acquisiton of31p spectra. Control
mice received saline instead of interferon. Anaesthetized mice were placed in
a SISCO 200-330 spectrometer at 4.7T, with the tumour positioned over a
double-tuned (iH/I3P) coil and maintained at 37°C. pH,, was estimated from the
chemical shift difference between the endogenous inorganic phosphate and ca-
NTP peaks and pH,,, from 3-APP and cx-NTP peaks.
The pH.,,, pH,,, and ApH values before and after interferon treatment were
calculated as 6.84, 6.98, -0.14, and 6.85, 7.27, -0.42 respectively. Paired t
tests showed that the negative ApH significantly increased (p<0.0Q1) due to a
significant increase in pHi,, (p<0.001). There were no significant changes in
pH,,. for the interferon-treated mice (p>0.5), nor in the pH,,, pH.,, and ApH
of the control mice (p>0.2).
The work presented herein shows that interferon significantly increased the
negative ApH ofHT29 tumours via an increase in pH,,,. Seymour etal., (SMR,
11, 6449, 1992, abstract), demonstrated that interferon increased the retention
of5-fluorouracil (5FU) in HT29 tumour cells. Work on isolated HT29 cells and
Lettre ascites cells showed that the greater the negative ApH across the tumour
cell membrane the greater the uptake of5FU by the cells (Ojugo et al., AACR,
36, 242, 1995, abstract). This suggests that interferon could modulate 5FU
activity on tumour cells by altering the tumour plasma membrane ApH.Oral Presentations 13
14 9 Cell cycle linked phosphorylation and cellular localisation regulates 4.9 Id HLH protein function Richard Deed', Eiji Hara 2, Gordon Peters2, and
John Norton'. 'CRC Department of Gene Regulation, Paterson Institute for Cancer Research, Chnstie
Hospital, NHS Trust, Wilmslow Road, M20 9BX UK. 'Molecular Oncology Lab, ICRF, Lincolns Inn
Fields, London WC2A 3PX, UK.
Members of the Id family of HLH transcription factors function as negative
regulators of DNA binding basic HLH proteins, and have been implicated in the
control of cell growth, differentiation and tumourigenesis by sequestering various
target bHLH proteins into an inactive state that is unable to bind DNA. We have
identified two mechanisms by which these functions of Id proteins are regulated.
Using transiently transfected Cos cells we show that in the absence of a bHLH,
"E" protein target, Id3 protein is localised exclusively to the cytoplasrm/perinuclear
region. Co-transfection with the E protein E47 results in nuclear translocation of
the Id3 protein. Id3 that is associated with the E protein displays an extended
half life, while the E protein itself is more rapidly turned over.
Using transiently transfected Cos cells and/or bacterially synthesised Id proteins,
we show that Id2 and Id3 are phosphorylated at a single site by a complex of
cyclins A or E and cdk-2 in vitro and in vivo. The phosphorylation state of the Id
protein regulates its ability to interact with different target bHLH proteins as
assessed by in vitro bandshift assays and in vivo reporter assays. In addition,
transfection of phospho-variant forms of Id proteins elicits marked effects on cell
cycle progression. These data identify two of the control mechanisms involved
in regulating the function of this class of cell cycle regulated molecule, that
represent potential therapeutic targets for the future development of novel anti-
cancer strategies.
5.2
Conversion of non-immunogenic tumour into an efficient antigen presenting
system using gene transfer. R.G. Vile, S. Castleden, N. Hardwick and H. Chong.
ICRF Laboratory ofCancer Gene Therapy, Hammersmith Hospital.
Previously, we have demonstrated the generation of anti-tumour immunity when
tumours are ablated with suicide genes. Whilst investigating the underlying
mechanisms, we observed induction of an intratumoural infiltrate ofmacrophages,
CD4+ and CD8+ T cells in B16HSVtk+ tumours being killedin vivo with ganciclovir
. In addition, distinct patterns ofcytokine expression were detected within the dying
tumours using rtPCR which closely resembles that of a Thl immune response (IL-2,
IL-12, TNF-a and IFN-y), which may reflect the anti tumour immunity in this
system. Using electron microscopy, DNA laddering and flow cytometry we have also
shown that B16/HSVtk+ cells die predominantly by necrosis, rather than apoptosis,
which may contribute to generation ofan inflammatory response within the tumour.
We are nowstudying the relationship between the levels of apoptosis induced by cell
killing (using suicide genes or conventional chemotherapeutic agents) and the
immunity produced following in vivo cell killing in several tumour cell types. These
data allow us to propose aunifying model for the generation ofanti tumour immunity
using gene transfer strategies.
To augment these effectsin vivo, we constructed bicistronic vectors in which two or
more genes are co-expressed. In a situation in which HSVtk or cytokine alone was
unable to eradicate B16 primary tumours, co-expression of IL-2 or GM-CSF with
HSVtk was able to ablate (IL-2) or reduce the primary tumour burden (GM-CSF).
However, GM-CSF/HSVtk was clearly the most effective combination in generating
systemic protection. Such vectors should be useful for both direct in vivo gene
delivery using targeted vectors (see Diaz et al) or for generation of tumour cell
vaccines (see Chong et al).
We are also investigating other factors which may influence the interaction of the
immune system with tumourcells, including the role the Fas/FasL system and ofheat
shock protein expression during tumour cell killing. Our data demonstrate that the
balance which exists between tumour tolerance and rejection in vivo can be
effectively manipulated in favour ofgenerating an immunostimulatory intra tumoral
environment using gene transfer strategies.
5.1 INTRACELLULAR AND EXTRACELLULAR EXPRESSION
OF THE CARBOXYPEPTIDASE G2 ENZYME FOR
ACTIVATION OF A MUSTARD PRODRUG IN GENE-DIRECTED ENZYME
PRODRUG THERAPY (GDEPT). C.J. Springer*1, R.A. Spooner1 2, Y. Light2,
J. Martin', S. Stribbling , F. Friedlos1 and R. Maraisy. 1 CRC Centre for
Cancer Therapeutics at the Institute of Cancer Research, 15 Cotswold Road,
Sutton, Surrey SM2 5NG, U.K. 2CRC Centre for Cell & Molecular Biology at the
Institute of Cancer Research, 237 Fulham Road, London, SW3 6JB, U.K.
The gene for the bacterial enzyme carboxypeptidase G2 (CPG2) was
expressed internally in mammalian cells. Human tumour cell lines A2780, SK-
OV-3 (ovarian adenocarcinomas), LS174T and WiDr (colon carcinomas) were
engineered to express constitutively either CPG2 or bacterial 0-galactosidase.
These cell lines were subjected to a GDEPT regime, using the prodrug 4-[(2-
chloroethyl) (2-mesyloxyethyl)amino]benzoyl-L-glutamic acid (CMDA). The lines
which expressed CPG2 had enhanced sensitivity to CMDA which was 11-95 fold
greater than the corresponding control lines. CPG2-expressing cells and control
cells were mixed in differing proportions, then treated with prodrug. Total kill
occurred when only 4-12% cells expressed CPG2, indicating a substantial
bystander effect.
CPG2 was also expressed tethered to the outer surface of mammalian
cells. Three positions were mutated to remove inappropriate glycosylation sites.
Human tumour cell lines (as above) were engineered for stable expression of
CPG2 on their surface and were subjected to GDEPT regimes with the CMDA
prodrug. The lines expressing CPG2 were 8-150 times more sensitive to CMDA
than non-expressing control lines. In bystandcer analyses, total cell kill occurred
when 2-19% of cells expressed CPG2 on their surface, indicating significant
bystander effects.
These results establish both the internally and the externally expressed
CPG2 with the CMDA prodrug system as effective combinations for the GDEPT
approach.
5,3
ADOPTIVE TRANSFER OF DENDRITIC
CELLS CAN DECREASE THE TUMORIGENICITY, AND
INCREASE THE IMMUNOGENICITY, OF A MOUSE
MELANOMA MODEL IN VIVO. A.A. Melcher, G. Hutchinson', I.
Hart', R.G. Vile. ICRF Laboratory of Cancer Gene Therapy,
Hammersmith Hospital; ICRF/Richard Dimbleby Department of
Cancer Research, St Thomas' Hospital, London.
Neither vaccination with irradiated cells, nor surgical excision of a
primary tumour, confers protection against a subsequent tumour
challenge with B16.FI cells. In contrast, ganciclovir-mediated in vivo
killing of established B16 tumours expressing the HSVtk gene
generates short term protection to rechallenge (upto 60 days) in all
animals and long term protection in 30% of mice, possibly due to
enhanced tumour antigen release and presentation.
Therefore, to enhance further the immunogenicity conferred by the
HSVtk/GCV system, we have prepared dendritic cells (DC) from
C57BL/6 mice syngeneic with B16 cells. Cells cultured over 8 days
from bone marrow using GM-CSF showed typical dendritic
morphology. In addition, FACS analysis showed positive staining for
surface molecules critical for antigen presentation, including MHC
Class I and II, B7.1 and B7.2 and functional analysis in an allogeneic
mixed lymphocyte reaction showed DCs to be significantly more
potent at antigen presentation than splenocytes.
To investigate whether the DCs could enhance the immunogenicity of
B16 cells killed in vivo with HSVtk/GCV, I0 B16tk+ tumours were
inoculated subcutaneously either alone or mixed with 103-1I 4 freshly
isolated DC. Before GCV treatment was initiated, in one representative
experiment, 8 of 8 animals developed palpable primary tumours in
the group with no added DC; in contrast, only I of 8 animals
developed palpable tumours when DC were present. All palpAble
tumours resolved with GCV treatment and, as shown previously,
typically 30% of animals were protected against rechallenge in the
group which did not receive DC. However, 70% of animals in which
DC were present during tumour seeding, and subsequent killing,
remained tumour free long term (>3 months).
These data suggest that professional antigen presenting cells at the site
of a growing tumour can reduce its tumorigenicity and can further
increase the immunogenicity of the tumour cells when they are killed
in vivo with suicide genes. From these data, we are currently
investigating protocols by which adoptively transferred DC can be
used to elicit protection against tumours in vivo.14 Oral Presentations
5.4
Hybrid LTR Retroviral Vectors to Confer Tissue-Specific Gene Expression in
Melanoma Cells. R.M. Diaz+, I.R Hart', & RG. Vile*.
+ICRF/Richard Dimbleby Department, St Thomas' Hospital, *ICRF Laboratory of
Cancer Gene Therapy, Hammersmith Hospital, London.
We are developing tissue specific vectors for the targeted gene therapy ofmelanoma.
Plasmid vectors containing a 200bp enhancer element (-2.Okbp to - 1.8kbp) of the
human tyrosinase promoter linked to a 380bp minimal tyrosinase promoter directed
reporter gene expression to levels which reached 50% ofthat of SV40 in MeWo cells
(human melanoma), butwere essentially silent in non melanoma cells. Therefore, we
have generated retroviral vectors with different combinations of small regulatory
sequences inserted into the viral LTR.
Replacement ofthe viral promoter with the tyrosinase promoter led to a loss oftissue
specificity. However, in a panel of 5 melanoma and 5 non-melanoma cell lines,
replacement of the viral enhancer with the tyrosinase enhancer conferred tissue
specificity and high viral titres (105 pfu/mL). For example, there was a6 fold increase
of GM-CSF production from MeWo cells infected with the enhancer- replacement
vector, relative to an enhancer deleted vector, in contrast, only a 1.4 fold increase was
observed in HeLacells. Interestingly, replacement ofthe viral enhancer and promoter
with thetyrosine enhancer andpromoter gave no detectable expression, suggesting that
this combination is not compatible with a functional viral LTR Vectors in which the
tyrosine enhancer was cloned upstream ofthe viral enhancer gave levels ofGM-CSF
approaching 100% ofthose produced by the wild type LTR vector in melanoma cells;
in contrast, in non melanoma cells, production did not exceed 45% ofwild type LTR
levels, suggesting that the tyrosinase enhancer can repress the activity ofthe adjacent
viral enhancer. Finally tandem repeats ofthe core enhancer element are being cloned
upstream ofthe SV40 promoter within the LTR to increase levels ofgene expression.
A bicistronic cassette, in which HSVtk and GM-CSF can be expressed from a single
promoter, has now been cloned into tyrosinase enhancer hybrid LTR vectors. These
vectors have been packaged into the FLYA18 cell line to yield high titre virus stocks
which should beresistant to human complement and which co-express both therapeutic
genes in atissue specific manner.
5.6 COMPARISON OF THE FUNCTIONAL
ACTIVITES OF FOUR MUTATIONS AFFECTING THE OLIGOMERISATION DOMAIN OF p53. ME Lomax", DM Barnes2, R Gilchrist', SM Picksley3, RS Camplejohn' 'Richard Dimbleby Dept. Cancer Res., UMDS, St. Thomas' Hosp., London, SEI 7EH, 2ICRF Clin. Oncol. Unit, Guy's Hosp., London, SEI 9RT, 3CRC Cell Transf. Group, Dept. Biochem., Univ. Dundee, Dundee, DDl 4HN.
Two functional assays for p53, an apoptotic assay and the yeast
based functional assay for the separation of alleles in yeast (FASAY)
were employed to determine the functional defect in a Li-Fraumeni like family described by Barnes et al. (Lancet 1992 340 259). The results of these assays suggested that this patient had a p53 related defect which was a germline mutation ofthe p53 gene. Sequencing of the p53 cDNA and genomic DNA revealed there to be a missene mutation at codon 337 resulting in a substitution of cysteine for arginine. This mutation lies in the oligomerisation domain of the p53 protein and the mutated protein retains some tranactivational activity in yeast as demonstrated by the FASAY. This mutation may lead to the formation of p53 dimers, not tetramers which are required for efficient transactivational activity.
Varley et al. (Oncogene 1996 12 2437) described a Li-Fraumeni family in which there was a missense mutation in the oligomerisation domain ofp53 leading to a substitution of proline for leucine at codon 344. PepPlot analysis suggests this mutation to be an inactivating mutation as it severely disrupts the structure of the oligomerisation
domain and results from the FASAY also point to this mutated protein having no transactivational activity.
These two mutated p53 genes, along with two other interesting oligomerisation mutants (349STOP and 337 Arg to His) have been generated in an E. coi expression plasmid by site directed mutagenesis
and expressed in E. coli. The resulting proteins were purified and their ability to bind to DNA and mdm2, their efficiency to bind to DNA, their requirement of activation by Pab421 for binding to DNA and how the proteins oligomerise, eg. tetramer, dimer or monomer, was assessed.
In addition, the four mutations were generated in a mammalian cell expression plasmid also by site directed mutagenesis and the plasmid was transfected into Saos-2 cells. The ability of the resulting proteins to transcriptionally transactivate endogenous target genes, such as p21, induce apoptosis and suppress transformation was also assessed.
5.5 TARGETING RETROVIRAL PARTICLES TO
MELANOMA CELLS BY INCORPORATION OF a-
MSH PEPTIDE INTO THE VIRAL ENVELOPE K. Sunassee*', F.
Morling2, F-L. Cosset', S.Russell2, R Vile'. 'Lab. Cancer Gene Therapy, Hamersmith Hospital, Du Cane Road, London; 2Cambridge Centre for Protein
Engineering, Cambridge; 3Centre de Genetique Moleculaire et Cellulaire, Centre
National de la Researche Scientifique UMR106, Universite Claude Bemand Lyon -I, Villeurbanne, Cedex, France
Many melanoma cells over-express the a-Melanocyte Stimulating Hormone Receptor (a-MSH R). To target gene delivery to melanoma, we engineered the a-MSH peptide into the Moloney Leukaemia Virus (Mo- MLV) envelope. The a-MSH peptide was placed at the N-terminus of the
env gene (MSH-SU) or a-MSH together with an IEGR Protease Xa cleavage sequence (MSH-IEGR SU), replaced the natural viral RHKR
sequence adjacent to the pl5E region of the TM domain. Following transfection into Tel.Ceb6 cells, viral supematants were generated from pooled populations of phleomycin resistant producer cells. Immunoblotting showed that both types of a-MSH-fusion envelope proteins were incorporated into the viral envelope, as effectively as wild- type ecotropic Mo-MLV glycoproteins. MSH-SU virus infected both NIH3T3 fibroblasts and murine melanoma Melan-A cells, as efficiently as Mo-MLV, as measured by ,B-gal reporter gene expression. However, human melanoma cell lines, MeWo and HMB-2 were not infected. MSH- IEGR virus did not infect any of the cell lines tested, before or after proteolytic cleavage with protease Xa. Both MSH-IEGR SU and MSH-SU virus were able to penetrate MeWo cells by endocytosis and could infect, only when co-intemalised with adenovirus, which aided endosomal
escape. MSH-SU virus also showed enhanced binding to MeWo cell surface receptors (4°C), compared to that observed for wild-type virus, however, the levels of binding (-2.5% of MSH-SU virus) were very low. Radioiodinated MSH-SU virus was also able to compete with a-MSH peptide, for binding to MeWo cells at 4°C. Although, MSH-SU is able to bind to cell-surface receptors on MeWo cells, and can penetrate the cells via endocytosis, infection can not occur unless the viral particles escape the endosome. Despite the successful incorporation of the a-MSH peptide into the viral SU, its size and/or its binding affinity may be too small to over-ride the binding of the natural ecotropic segment still present in the fusion env SU. This suggests that a novel peptide insert must achieve a critical size to confer novel binding specificity to Mo- MLV particles for targeted gene delivery. Further characterisation of these novel retroviral particles will be described.
5 7 EXOGENOUSWILD-TYPEpS3 INDUCES APOPTOSIS IN 5.7 Hep3B, R. R. Mitry andN.A. Habib, Department ofSurgery,Royal Postgraduate Medical School, Hammersmith Hospital, Du CaneRoad, LondonW12 ONN
Hep3B is a human hepatocellular carcinoma (HCC) cell line that does not express endogenous wild-typepS3 (wt-pS3) due to a major deletion in the p53 gene.' Using the liposomal transfection reagent DOTAP (Boehringer Manheim Ltd., East Sussex, UK), Hep3B cell cultures were transfected with pC53-SN3 plasmid (pCMV-Neo-Bam vector with wt-p53 cDNA encoded into it), while the control cultures were treated with DOTAP only. 24 hr post-transfection and using Northern Blotting, and PCR/RT-PCR techniques, the cultures were checked for the transfer andexpression ofexogenouswt-p53 gene. The PCR/RT-PCR were carried out in the presence of specific primers for wt-p53 and
neomycin resistance marker gene (neor ) encoded by the PC53-SN3 plasmid. The cultures
were checked for the presence/absence of apoptosis, using three techniques: propidium iodide (PI) DNA labeling, DNA fragmentation assay, and electron microscopy(EM). The PCR results showed the presence ofne6! marker gene in the cultures transfected with pC53-SN3/DOTAP and not in the control cultures. TheNorthern Blotting results showed that there was wt-p53 expression, this was confmned by the RT-PCR results, which also demonstrated neo'expression, only in the pC53-SN3/DOTAP transfected cultures. The fluorescencemicroscopyappearance ofthePI-labelled cell nuclei showed the characteristic apoptotic morphology where chromatin condensation and nuclear fragmentation were observed in the pC53-SN3 transfected cultures compared to the control cultures which
werenegative. ThePI-stainingtechnique was also useful inestimating the efficiency ofthe cultures growth. The control cultures grew -5-fold more efficiently than the pC53-SN3 transfected cultures. A characteristic apoptotic large DNA fragments ladder pattem was observed in the pC53-SN3 transfected cultures and not in the control cultures. The EM results confmned that many ofthe cells in the pC53-SN3 treated cultures were apoptotic, noticeably by the presence of many apoptotic bodies, with many cells presenting the characteristic signs of apoptosis such as chromatin condensation, margination and nuclear fragmentation. Some of the apoptotic bodies were being phagocytosed by neighbouring non-apoptotic cells.
In conclusion, in vitro transfection of the HCC cell line Hep3B with wild-type p53 gene resulted in wt-p53 transfer and expression which induced apoptosis, confirming that wt- p53 is atunour suppressor gene for HCC cells which do not expresswt-p53.'
References
1. Bressac B. etal. (I1990)Proc. Natl. Acad. Sci. USA 87, 1973-1977.
2. Puisieux A. etal. (1993)FASEBJ. 17, 1407-1413.
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Temperature Sensitive DNA Damage Response of Wild-type p53 Cells
5.8 Transfected with theDoyminant Negative p53 Mutant(eodon 143 valtoaa
Melanie M Morrisal. A. C. MCDonaldl, N. Jones and R. Hrowsn.1CRC Dept. Medical Oncology, CRC
Beatson Laboratories, SwitchbackRd Glasgow, G61 IBD. 2Dept. Cellular and Molecular Biology, School
ofBiological Sciences, Stopford Building, University ofManchester, Manchester.
The dominant negative p53 mutant, codon 143: valine to alanine, has recently been
shown to exhibit a temperature sensitive phenotype when expressed in a p53 null
background (Friedlander P. et al., 1996, Mol Cell Biol, 16, 4961). Phenotypic effects
were demonstrated by increased DNA binding, transactivational activity, and a switch
to wild type conformation at the permissive temperature (320C). We have further
examined the effect of temperature on clonogenic cell survival and cell cycle
progression following ionising radiation (IR) in wild-type p53 cells transfected with
this mutant p53 (A2780 mp53 143).
Incubation of the parental and vector alone controls at 32°C resulted in loss
of plating efficiency (PE: 0.2 ± 0.16% at 32°C, 22.3 ± 7.8% at 37°C). In contrast, the
mutant transfectants exhibited an increased ability to clone at 32°C (PE: 4.5 ± 1.8% at
32°C, 22.7 ± 10.9% at 37°C). Westem blot analysis of the parental A2780 cell line
showed that on incubation at 32°C, a dramatic induction of wild type p53 ensued.
Clonogenic assessment of A2780 mp53 143 cell survival at 37°C resulted in a 2.3 fold
resistance toIR, as compared to the vector alone controls. Notably, incubation at 320C
for up to 8 hours following IR, resulted in reduction of this IR resistance and longer
exposures to 32°C resulted in a sensitivity profile similar to the vector alone control.
Consistent with this observation, IP analysis showed increased p53 in wild-type or
supressor conformation following incubation at 320C.
Further, we have demonstrated that A2780 mp53 143 lose the ability to arrest
in GI following IR-induced DNA damage at 37°C. Incubation at 32°C however causes
the A2780mp53 143 to regain an IR induced GI arrest (ratio of total S-phase cells 24
hrs post IR: unirradiated controls = 1.05 ± 0.4 at 37°C and 0.3 ± 0.1 at 32°C),
confirming the tempertaure sensitive nature of this mutant.
We have thus demonstrated that in a wild type p53 background, the dominant
negative p53 mutant, codon 143 valine to alanine, exhibits a temperature sensitive p53
response. Furthermore, we now demonstrate that this phenotype is functional in terms
of the cellular response to IR-induced DNA damage.
6.1
c-ERBB-4 EXPRESSION IN PRIMARY OVARIAN CANCER
SP Langdon, BiB Simpson, KG Macleod, EP Miller, GJ Rabiasz,
JF Smytb and WR Miller. ICRF Medical Oncology Unit, Western General Hospital,
Edinburgh, EH4 2XU
Members of the ErbB (type I) family of tyrosine kinase receptors are frequently
overexpressed in many human cancers and increased expression of both EGF receptor
(ErbB-1) and ErbB-2 have been associated with poor survival in ovarian cancer. ErbB-4
has recently been described (Plowman et al, PNAS, 90, 1746, 1993) and like ErbB-3 is
activated by heregulin. These receptors are now recognised to be highly interactive and
preliminary evidence from ovarian cancer cell line models suggests that heregulin acting
via either ErbB-4 or ErbB-3 can activate ErbB-2 and either stimulate or inhibit ovarian
cancer cell growth (Xu et al, Proc AACR, 37, 191, 1996). Although these results suggest
a possible functional role for ErbB-4 in ovarian cancer, no data has been published on the
incidence of ErbB-4 in primary ovarian cancer.
We have investigated the expresssion of ErbB-4 in a series of ovarian tumours using
immunobistochemistry, Western blot analysis and reverse-transcription PCR (RT-PCR).
Immunobistocbemical analysis of 23 malignant ovarian carcinomas using the C18
polyclonal antibody (Santa Cruz Biotech) indicated expression within all sections
examined. Expression was found almost exclusively in epithelial cells with only
occasional stromal staining. Co-incubation of the sections with the control peptide
against which the antibody was raised blocked staining and suggested specificity.
Western blot analysis indicated the presence of a band at 180 kDa consistent with ErbB-4
in all specimens examined but the presence ofother bands also. To assess RNA
expression, RT-PCR was undertaken on RNA extracted from 25 specimens. All specimens
demonstrated a signal for Y-actin but under the PCR conditions used only 8 of these
demonstrated a signal for ErbB-4. Of these 8 positive samples, 7 were of serous
histology compared to 5 of 16 negative specimens indicating a significant association
with serous histology (p = 0.01); all 8 positive samples were advanced stage (Iln I V)
compared to 7 of 16 negative samples (p= 0.001) and the survival of the positive sample
group was significantly reduced compared to the negative sample group (p=0.0013;
log-rank). Although the inconsistency between protein and RNA expression data
requires resolution, it is clear that many primary ovarian tumours express ErbB-4 and
expression may be increased in advanced disease.
5.9 ONCOLYTIC ADENOVIRALTHERAPY FOR
RECURRENT p53(-) HEAD AND NECK CANCER
I. Ganly', D. Soutar', G. Robertson2, S.B. Kaye2, A. Balmain3. D. KiM4.
'Canniesburn Hospital, 2Beatson Oncology Centre, Western Infirmasy and
3CRC Beatson Laboratories, Glasgow. 4Onyx Pharmaceuticals, 3031 Research
Drive, Richmond, California, USA.
Mutation of the p53 tumour suppressor gene is the most common
genetic alteration found in human cancers. It is mutated in over
50% of all human cancers and in head and neck cancer the
frequency of mutation is 50-80%. We have a p53 dependent
oncolytic adenovirus which selectively replicates in and lyses p53(-)
cell lines. Cytopathic effect assays were carried out on a range of
p53(-) and p53(+) tumour cell lines. Cells growing on culture plates
were infected with an E1B deleted adenovirus DL1520 at 1 and 10
pfiu/cell and the cell lines monitored for cytolysis.
Immunocytochemistry using an anti-hexon protein fluorescent
antibody was carried out at 96 hrs post-infection. DL1520 virus
produced cytolysis only in p53(-) cell lines. All cell lines showing
cytolysis stained positively with anti-hexon protein antibody
indicating viral replication was occurring. p53(-) tumour xenografts
were then formed in nude mice and the tumours injected directly
with virus. 6 weeks post-injection, partial or complete regression of
tumours had occurred. Based on these in vitro and in vivo studies,
we are carrying out a Phase I clinical trial involving direct
intratumoural injection of E1B(-) adenovirus into p53(-) recurrent
head and neck cancer patients.
6.2 FUNCTIONALI=YOFTHE PROGESTERONE RECEPIOR IN
OVARIANCANCERANDlTS REGULATION BYOESIROGEN
SP Langdon, H Gabra, GJ Rabiasz, AA Ritchie, JMS Bartlett, RA Hawkins,
JF Smyth and WR Miller. ICRF Medical Oncology Unit, Western General
Hospital, Edinburgh EH4 2XU
There is increasing evidence to suggest that the progesterone receptor (PR) has
a functional role in the genesis and growth regulation of ovarian cancer. Recently,
a mutation in the PR gene has been associated with a 3-fold increased risk of non-
familial ovarian cancer (Kieback et al, Proc AACR, 37,1704,1996). We have
previously shown that loss of heterozygosity (LOH) at the site of the PR gene
(llq22) correlated with low PR content and was associated with poor survival in
oestrogen receptor (ER)-positive tumours (Gabra et al, Clin Cancer Res, 1, 945,
1995). In contrast where there was no LOH, ER levels correlated with PR and
ER-rich tumours had good survival suggesting that PR may counter growth-
stimulatory effects mediated through the ER.
In a series of 74 primary ovarian carcinomas, PR content was significantly
associated with ER content (p < 0.0001: Pearson correlation). Such an association
suggests the presence of oestrogen regulation in these tumours. The association was
different between histological types being strong for endometrioid (p< 0.0001) and
mucinous carcinomas (p< 0.0001) and absent in serous (p=0.31) and clear cell
carcinomas (p=0.86). The loss of association for serous and clear cell may well be
due to structural alteration at the PR locus (Gabra et al, Clin Cancer Res, 1, 945,
1995). Increased expression of PR was associated with improved survival in this
group and patients with a tumour PR content > 40 fmollmg protein had significantly
better survival than patients whose tumours contained < 40 fmol/mg protein
(p=0.0007 log-rank test).
To obtain evidence that PR may be functional in ovarian cancer, we examined the
effect of the progestin megestrol acetate (MA) against the PR-positive PE04 ovarian
carcinoma xenograft. Subcutaneous administration of MA ( 1.5 mg ; 60-day slow
release pellet) resulted in. significant tumour growth inhibition. Evidence of
oestrogen regulation of PR in this model was obtained by the use of endocrine
manipulation. PR content of the PE04 xenograft in adult female nude mice was
145 fmollmg protein and this fell to 7 fmollmg in ovariectomised mice and was at a
level of 2 fmollmg protein in male mice. Administration of 17 , -oestradiol (E2) via
slow-release pellets increased PR content to 745 fmollmg protein which coincided
with growth-inhibition consistent with the view that PR may mediate a growth-
inhibitory response. The levels of PR correlated with serum E2 concentrations.
All these data point to PR mediating a growth-inhibitory effect and being regulated
by oestrogen in ovarian cancer.16 Oral Presentations
6.3 ER EXPRESSION AT RELAPSE ON TAMOXIFEN
PREDICTS FOR SECOND-LINE ENDOCRINE
RESPONSE IN ADVANCED BREAST CANCER Johnston SRD *, Saccani-
Joti G, Ebbs SR, Smith IE, Dowseat M. Academic Department of Biochemistry
and The Brcast Unit, Royal Marsdcn Hospital, London, SW3 6JJ; Mayday
University Hospital, Croydon.
It is recognised that response to second-line endocrine therapy in
advanced breast cancer is more likely in patients who had an objective
response to tamoxifen given as first line therapy for metastatic disease.
We have previously shown that in primary tumours with acquired
tamoxifen resistance ER expression is often maintained at relapse,
although the quantitative levels of expression may be reduced (Cancer
Res. 55; 3331-38). In this study we wished to determine whether ER
expression and phenotype (PgR/pS2 expression) determined by
immuno-histochemistry (IHC) in the tamoxifen-resistant tumour at
relapse would predict for response to second-line endocrine therapy.
Primary tamoxifen had been given to 29 patients with locally advanced
or metastatic breast cancer, who at relapse had a biospy from
accessible disease prior to second-line endocrine therapy with either
aromatase inhibitors (Al), medroxyprogesterone acetate (MPA), or
other antioestrogens. There had been a previous objective response to
tamoxifen in 20 patients, with stable disease for 6 months in a further
3 patients. At relapse after a median of 28 months (range 9-106), a
further endocrine response was seen in 18/23 (78%) previous
tamoxifen responders, compared with only 1/6 (17%) who had
progressed on tamoxifen (p=0.001). 16 tumours expressed ER/PgR at
relapse on tamoxifen, of whom 15 (94%) responded to further
endocrine therapy. In contrast, of the 13 tumours which were ER-
/PgR- at relapse only 3 responded to further therapy. ER/PgR
expression was a better predictor for second-line response to Al than
prior tamoxifen response, as all responding tumours expressed
ER/PgR compared with none of the non-responders. The 3 ER-/PgR-
tumours at relapse on tamoxifen who responded to further therapy all
came from patients treated with MPA. In conclusion ER/PgR
expression determined by IHC at relapse on tamoxifen may be a strong
predictor for second-line endocrine response, especially to aromatase
inhibitors, and could be a useful predicitive test for patients who
relapse during adjuvant tamoxifen therapy where prior endocrine
response is unknown.
5 PROGNOSTIC SIGNIFICANCE OF HER2 AND HER4
HETERODIMERISATION IN CHILDHOOD
MEDULLOBLASTOMA R.J.Gilbertson*', R.H.Perry', A.D.J.Pearson' and J Lunec', 'Cancer
Research Unit, The Medical School, University ofNewcastle upon Tyne, Newcastle upon Tyne NE2
4HH, 'Departnent ofNeuropathology, Newcastle General Hospital.
The type I tyrosine kinase growth factor receptor (RTK I) family includes
the epidermal growth factor receptor and the related proteins HER2, HER3 and
HER4. Recent studies ofthis receptor family have revealed complex signaling
interactions involving the production of ligand mediated heterodimners that are
synergistic for the transformation ofcells in vitro. We have analysed the expression
(measured by immunohistochemistry) and prognostic significance ofall four family
members and their ligand heregulin-a in seventy cases ofchildhood
medulloblastoma (cPNET) at twenty five year follow up. Various patterns of
receptor and ligand co-expression were identified. HER2 and HER4 were the most
frequently expressed family members with 53% of cases expressing both proteins.
In multivariate survival analysis with clinicopathological disease features
no individual receptor or heregulin-c achieved significance. In contrast, when
considered together, co-expression of HER2 and HER4 demonstrated independent
prognostic significance (p=0.006) along with tumour mitotic percent index
(p<0.000 1), craniospinal radiotherapy dose (p=0.001), age (p=0.006) and tumour
stage (p=0.014).
Inorder to demonstrate heterodimerisation between HER2 and HER4 in this
disease we performed immunoprecipitation and Western blotting analysis in frozen
sections from patient primary tumours. HER4 and HER3 co-immunoprecipitated
with HER2 confirming the heterodimerisation ofthese receptors in
medulloblastoma.
Finally, we have also analysed expression of the AP-2 transcription factor
implicated in the positive regulation of HER2 and HER3 gene transcription in
malignant cells. AP-2 expression was significantly related to HER2, HER3 and
HER4 expression (p=0.034, p=0.024 and p<0.0001). AP-2 has not previously been
implicated in the control of HER4 transcription suggesting that the possible
regulation of HER4 transcription by AP-2 should be explored.
6.4 p27K'P' PROTEIN rN HUMAN BREAST CARCINOMA:
IMMUNOHISTOCHEMICAL STUDY REVEALS A POTENTIAL
PROGNOSTIC MARKER, E.J Shuter ', J.J. Anderson2, G.G. Mclntosh2, D. MCKenna2, I. Milton', M.
Steward', C.H.W. Homne23, J. Lunec', 'Cancer Research Unit, University ofNewcastleUponTyne, UK.
NE2 4HH, Dept. ofPathology, RVI, and'Novocastra Laboratories, Newcastle Upon Tyne, UK. NEI 4LP
Cdk inhibitors act to inhibitcyclin cdk complexes and prevent cell cycle
progression. We haveproduced a monoclonal antibody to a full length
recombinant fusion protein which allows an accurate and reproducible
determination ofthe levels ofthe cdk inhibitorp27K'P' expression in routinely
processed tissue. The specificity oftheantibody hasbeen demonstrated by western
blottingusing lysates ofthe mink lungepithelial cell line, MvlLu afterTGF-B1
induction. In our immunohistochemical study of202 primary breast carcinomas
74% displayed enhanced expression ofp27K't' protein. A significant correlation,
p=0.0262 using the log-rank test, was detectedbetweenp27K"" immunostaining
and increased time before relapse in a subset of53 tumours which were negative
forcyclinDl protein expression. This study suggests that in breast cancers which
are negative forcyclin Dl expression, the presence ofp27tKM' could indicate a
greater time before relapse, and as such p27'0t" could prove tobe a useful
prognostic marker in conjunction with cyclin Dt status.
URINARY TISSUEFACTORLEVELS IN CONTROLS AND 6.26 PATIENTS WITH CANCER. BA Lwaleed1, M Chisholm'
andJLFrancis2. 'Dept. ofHaematology, SouthamptonUniversity, Southampton, U.K.
and2Hemostasis and Thrombosis ResearchUnit, FloridaHospital, FL 32701, U.S.A.
Activation ofblood coagulation is a common complication ofcancer in man
and experimental animals1. The causes of such activation may be
multifactorial, but increased production of tissue factor (TF) the primary
triggerofblood coagulation2, by the hostmononuclearcellsmay be involved.
TF is not only produced by human monocytes (mTF) or even tumour cells,
but is also found in urine (uTF) where measurements might be of clinical
useful3. Using a highly standardized one stage kinetic chromogenic assay
developed by our group3, we measured uTF level in controls [healthy
volunteers (n=57) and patients with renal stones and a normal ESR (n=30)]
and in patients with benign and malignant diseases of the bladder (n=75),
prostate (n=106), breast (n=94) and large bowel (n=62). Each benign disease
group was divided into inflammatory and non-inflammatory categories.
Controls showed no significant difference with the benign groups except in
breast and large bowel disease (P<0.05, P<0.05 respectively). However, a
significant difference was observed between the controls and benign groups
when compared with patient with malignantdisease (P<0.001). All malignant
groupsdemonstratedasignificantdifferencewhencomparedwiththerelevant
non-inflammatory disease (P<0.05), but not with the inflammatory benign
disease. Cancer patients showed uTF activity above the upper quartile range
of the normal control group for bladder (74.4%), prostate (68%), breast
(77.3%) and large bowel disease (73%). In conclusionuTF measurements can
distinguish patients with malignancy from normal controls and benign non-
inflammatory disease, but not inflammatory disease. uTF may therefore have
a role in screening patients for certain malignant diseases.
References:
1) Francis JL. Med Lab Sci. 1989; 46: 331.
2) Nemerson Y. Semin Haemost. 1992; 29: 170.
3) Lwaleed BA, Chisholm M, Francis JL. BrJHaem. 1996; 93: 18.Oral Presentations 17
6.7 QUANTITATIVE FISH: CHROMOSOME 9 LOSS A
MARKER OF RECURRENCE IN TCC BLADDER?
JMS BartlettI, ADWatters1, JJ Going2, KM Grigor3 & TG Cooke1 Glasgow
Univ. Dept. ISurgery, 2Path, G3 1 2ER.. 3Univ. Dept. Path. Edin, EH8 9AG.
Estimation of chromosomal copy number, by pericentromeric repetitive
DNA sequences in interphase nuclei, provides valuable information in a
number of diseases including cancer. This study describes quantitative
determination of chromosome 9 copy number by fluorescence in situ
hybridisation (FISH) in transitional cell carcinoma of the urinary bladder
(TCC). Fixed tissue was used without disaggregation.
Observer and tissue related variability were evaluated for two measures,
mean signal/nuclear ratio (MSNR) and percent monosomic cell population
(MCP). Intra and inter observer variation for MSNR was consistently lower
than for MCP (Intra observer 6.35% vs. 29.73%, inter observer 4.00% vs.
15.02% respectively). In 98% of carcinomas analysed, consistency within
multiple tumour areas suggested that multiclonality/tumour heterogeneity
were uncommon at this locus; mean intra tumoural variation for MSNR was
6.1% and for MCP was 16.19%. Neither stage nor grade increased the
variability ofeither scoring measure.
Investigation ofTCC patients classified by recurrence and/or progression
demonstrated that loss of chromosome 9 occurs early. 86 TCC from 33
patients were analysed for loss at this locus using MCP & MSNR. Normal
ranges were defined for a control tissue (epidermis) and values for MSNR
below 1.51-2.10 denoted monosomy. 22 TCC were detected with
monosomic scores. Of 71 TCC, where multiple areas were analysed, 69
(97%) demonstrated the same chromosome 9 copy number in all areas (2-6);
2 tumours showed heterogeneity at this locus. Loss of chromosome 9
persisted in all subsequent TCC from patients who had lost this marker in
their primary TCC. 30% (6/20) of patients with subsequent carcinoma
recurrence demonstrated loss of chromosome 9 in their primary and all
subsequent TCC analysed. Patients (n = 11) with non-recurrent TCC did not
show loss ofchromosome 9 in their TCC (p = 0.047).
This study describes rapid quantitation of chromosomal copy number by
(FISH). Strict quality control demonstrates that this technique is
reproducible in a clinical environment and can be used to detect genetic
changes relevant to patient outcome. Loss of chromosome 9 indentified
patients at high risk ofrecurrence.
6.8 WAFI EXPRESSION IN TRANSITIONAL CELL
CARCINOMA OF THE BLADDER, K.L.Braithwaite",
J.K.Mellon2, D.E.Neal2, C.H.W.Horne3, C.Challen1, R.Abdel-Fattahl,
T.R.L.Griffiths2, K.M.Wood3 and J.Lunec', ICancer Research Unit, 2Department
ofSurgery, The Medical School, University ofNewcastle Upon Tyne, Newcastle,
NE2 4HH, 3Department ofPathology, Royal Victoria Infirmary, Newcastle Upon
Tyne, NE2 4LP.
The expression of WAFI, a downstream mediator of p53-
dependent cell cycle arrest, was studied using
immunohistochemistry in 173 cases of assorted stage and grade of
transitional cell carcinoma of the bladder. The WAFI specific
staining of tumour cells was nuclear and often heterogeneous
throughout the section. The staining of a higher percentage of cells
in the papillary regions of low stage tumours was particularly
striking. Low stage tumours contained a significantly higher
percentage ofWAF1 positive nuclei than muscle-invasive tumours
(p=0.0002, Mann-Whitney test). High grade G3 tumours had a
significantly lower WAF1 score than lower grade GI or G2
tumours (p=0.0056 and p=<0.0001, respectively, Mann-Whitney
test). A significant inverse relationship was found between the
levels ofprotein detected by immunohistochemistry for WAF1 and
p53 (p=1.46 x 10-5, regression analysis) and WAFI and the cell
proliferation marker Ki67 (p=0.024, regression analysis). No
significant association was found with WAF1 positivity and
tumour progression, progression-free interval or tumour recurrence
rate in superficial disease. In the patient group with invasive (T2-
T4) tumours, a high percentage of WAF1 positive cells was
associated with better survival by log-rank test, which reached
significance (p=0.034) when the classification into high and low
staining groups used a cut-offof60%.
6 9 Allelotype ofBarrett's adenocarcinoma; a searchfor novel
tumour suppressor genes
K Dolan, J Garde2, A Swit2, J Gosney', S Khan, SJ Walker, R Sutton, JK Field2.
Departnents ofSurgery and 1 Pathology, Royal Liverpool University Hospital,
Liverpool, L7 8XP.
2Molecular Genetics and Oncology Group, Clinical Dental Sciences,University of
Liverpool, Liverpool L69 3BX.
Loss offunction oftumour suppressor genes have beenimplicated in the
development ofdysplasia and carcinoma m patients withulcerative colitis. We have
performedloss ofheterozygosity (LOH) studies on 22 cases ofadenocarcinoma
occurring in Barrett's oesophagus, in orderto determine the role oftumour
suppressor genes in the Barrett's metaplasia--dysplasia--carcinoma progression.
Tissue was obtained from the tumour and from normal gastric mucosa (control),
and snapped frozen before microdissection. The genome ofeach tumour was studied
using 110 microsatellite markers, covering allnonacrocentric autosomal chromosome
arms.
The sites most frequently demonstrating LOH were found on 3p (56%), Sq (50%),
9p (50%), lip (44%), 13q (50%), 17p (81%), 17q (94%) and 18q (69%). At least
seven microsatellite markers were used for each ofthese chromosomal arns. LOH
on 3p, 9p, 13q, 17p and 18q occurred mainly at the sites ofthe VHL, MTS 1, Rb, p53
and DCC tumour suppressor genes respectively.
The greatest area ofLOH on 5q occurred at a site distant to the APC tumour
suppressor gene,indicating thepossibility ofanother tumour suppressor gene on Sq.
Similarly, the majority ofLOH on I lp did notinvolve the WTI tumoursuppressor
gene. The refined areas on Sq and Ip are thus putative sites ofnovel tumour
suppressor genesinvolvedin the development ofBarrett's adenocarcinoma. Itis of
note that the greatest degree ofallelic imbalance was found on 17q (94%), with 68%
oftumours displaying LOH at 17ql1.2-qI2. We propose thatthis is the site ofthe
main tumour suppressor gene associated with the development ofadenocarcinoma
in Barrett's oesophagus.
Fractional allele loss (FAL) was calculated for each tumour, andthe median FAL
was 0.22. FAL was not significantly related to the stage ofthe tumournorprognosis.
However, tumours displaying LOH at the site ofthe MTS I tumour suppressor gene
had a significantly higher FAL than thoseretaining heterozygosity, and all ofthese
tumours with LOH at this site demonstrated microsatellite alterations with other
microsatellite markers. LOH at the site ofthe MTS I tiunour suppressor gene may be
associated with widespread genomic instability.